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Chapter	  1	  -­‐	  Introduction	  
 
Proline is unique among the twenty amino acids because of its cyclic nature. So 
nature has evolved unique enzymes for metabolism of proline. Proline is catabolised to 
glutamate by a set of two enzymes, proline dehydrogenase and pyrroline-5-carboxylate 
(P5C) dehydrogenase. Proline dehydrogenase catalyzed the oxidation of proline to P5C. 
In the process, FAD gets reduced, transfers its electron to the electron transport chain and 
subsequently reoxidized for the next round of catalysis. Pyrroline-5-carboxylate is 
hydrolyzed to glytamyl-γ-semialdehyde (GSA) by non-enzymatic hydrolysis, and is the 
actual substrate for P5C dehydrogenase. P5C dehydrogenase oxidizes glutamyl-γ-
semialdehyde to glutamate with concomitant reduction of NAD+ to NADH (Fig. 1.1).  
Structure	  and	  organization	  of	  proline	  catabolic	  enzymes	  –	  	  
Proline dehydrogenase and P5C dehydrogenase are present in all organisms from 
archaebacteria to human. There are three different types of domain organization for these 
enzymes, which are present in different organisms1(Fig. 1.2). In some bacteria, proline 
dehydrogenase and P5C dehydrogenase activities are on the same polypeptide chain. 
These bifunctional enzymes are called Proline utilization A (PutA). The examples are 
PutAs from Bradyrhizobium japonicum, Rhodopseudomonas palustris, and Nitrobacter 
hamburgensis. Besides proline dehydrogenase and P5C dehydrogenase activity, some 
PutA, known as trifunctional PutA, also have a DNA binding domain. In the absence of 
proline, DNA binding domain binds to the promoter of its own gene causing its 
repression2. Reduction of proline dehydrogenase domain by proline causes 
conformational changes in the flavin isoalloxazine ring and ribityl side chain, inducing 
reorganization of the hydrogen bonds around flavin. These structural changes, in and 
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around FAD, decreases the afinity of PutA to DNA and increases its membrane 
association3,4. Thus it has an autorepressor function. These trifunctional PutAs are present 
in bacteria such as Escherichia coli, Salmonella typhimurium, and Bordetella.  Some 
bacteria and eukaryotes have these two catalytic activities on separate polypeptide chains 
for example Thermus thermophilus, yeast, and human. Monofunctional P5C 
dehydrogenases are 515-575 residues long. However, proline dehydrogenases are 300-
550 residue long with the mammalian proline dehydrogenase being longest (551 residue) 
and bacterial proline dehydrogenases being shortest (300 residue).  
The Structures of the DNA binding5 and proline dehydrogenase domain of 
trifunctional PutA6 from Escherichia coli have been solved by the Tanner group. The 
structure of the monofunctional proline dehydrogenase from Thermus thermophilous, has 
also been solved1. The 300 residues of Thermus thermophilous proline dehydrogenase is 
the minimum requirement to form a catalytically active proline dehydrogenase. Besides 
this catalytic core, human proline dehydrogenase also has an about 250 residue long N-
terminus of unknown function. Proline dehydrogenases adopt a distorted (βα)8 barrel or 
TIM barrel. It has 8 parrallel β strands making the center of the barrel with 8 α helix 
arrayed outside the barrel next to each β strand. Rather than sitting alongside the β8 
strand, the α8 helix sits on top of the barrel and provides sidechains that interacts with 
the substrate, proline1, 6-7.  The FAD cofactor binds at the C-terminal end of the strands of 
the barrel with its re face tightly packed against the strands and se face available for the 
hydride transfer from the substrate proline.  
Proline	  catabolism	  in	  eukaryotes	  –	  	  
In eukaryotes, proline dehydrogenase and P5C dehydrogenase are localized in 
mitochondria. While proline dehydrogenase is found attached to inner mitochondrial 
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membrane8,8b , P5C dehydrogenase is a soluble enzyme present in the mitochondrial 
matrix9,10. Proline metabolism connects three different metabolic pathways and involves 
two other amino acids11 (Fig. 1.3). Proline gets oxidize to glutamate, which can enter the 
TCA cycle as α-ketogluterate after deamination. Ornithine amino transferase converts 
ornithine to γ-glutamyl semialdehyde or pyrroline-5-carboxylate thus connecting proline 
metabolism to the urea cycle. Oxidation of proline to P5C in mitochondria, transport of 
P5C to cytosol where it is reduced to proline by P5C reductase and transport of proline 
back to mitochondria forms a redox shuttle which transfers redox equivalent from the 
pentose phosphate pathway to the electron transport chain12. 
Role	   of	   proline	   dehydrogenase/oxidase	   and	   P5C	   dehydrogenase	   in	  
diseases	  –	  	  
Expression of proline dehydrogenase is induced by P5314 and peroxisome 
proliferator-activated receptor γ (PPARγ)15. Further , a decrease in ATP:ADP ratio and an 
increase in AMP causes activation of AMP dependent protein kinase (AMPK). AMPK 
activation elicits the induction of proline dehydrogenase through the down-regulation of 
mTOR16. Proline dehydrogenase, during the oxidation of proline to pyrroline-5-
carboxylate, generates reactive oxygen species in a proline dependent manner17. Reactive 
oxygen species generated, induces apoptosis through extrinsic and intrinsic pathway18 
(Fig. 1.4).   
The structure of P5C dehydrogenase from Thermus thermophilus has been solved 
by Inagaki et. al.19. P5C dehydrogenase is an aldehyde dehydrogenase which catalyzes 
the oxidation of γ-glutamyl semialdehyde to glutamate. Several mutations in the human 
P5C dehydrogenase gene has been reported11. Some of them are known to cause loss of 
P5C dehydrogenase activity and type II hyperprolinemia20. 
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Summary	  of	  research:	  	  
My Ph.D. research work is divided into three parts. In the first part, I have 
crystllized and solved the structure of E. coli PutA86-630 inactivated with N-Propargyl 
glycine. N-Propargly glycine irreversibly modifies FAD, mimicking the reduced state of 
FAD. This structure helped in understanding the conformational changes in the protein 
associated with FAD reduction. In the second part of my Ph.D work, I have crystallized 
and solved the structure of the bifunctional PutA from Bradyrhizobium japonicum. The 
structure shows a 40 Å long channel, which connects the proline dehydrogenase and P5C 
dehydrogenase active site and suggests the direct transfer of intermediate from one active 
site to the other. This phenomenon, known as substrate channeling, was supported by 
kinetics. Further, I used equilibrium analytical ultracentrifugation and small angle X-ray 
scattering to study the oligomeric state of Bradyrhizobium japonicum PutA in solution. In 
the last part, I have crystallized and solved the structure of P5C dehydrogenase from 
three different source; human, mouse, and yeast (saccharomyces cerevisiae). The 
structure of a human P5C dehydrogenase mutant was solved. Oligomeric states of these 
P5C dehydrogenases has been studied by equilibrium analytical ultracentrifugation. 
Effect of different mutations on the catalytic activity of enzyme was studied by kinetics 
and NAD+ binding affinity was measures by isothermal titration calorimetry.  
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Figure legends –  
Figure 1.1 – Schametic of proline catabolism. Adopted from Amino Acids  2008, 35 (4), 
719-30. 
Figure 1.2 – Different domain organization of proline dehydrogenase and P5C 
dehydrogenase. 
Figure 1.3– Schemetic of the proline metabolic pathway connecting pentose  phosphate 
pathway, urea cycle, and TCA cycle. Figure adopted from Phang et. al. 
201013. 
Figure 1.4 – Induction of apoptosis by reactive oxygen species, generated by proline 
oxidase. Figure taken from Phang et. al. 200818. 
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Figure 1.1: Schametic of proline catabolism 
 
 
 
Figure 1.2: Different domain organization of proline dehydrogenase and P5C dehydrogenase. 
 
 
 
 
 
Figure 1.3: Schemetic of the proline metabolic pathway 
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Figure 1.4: Induction of apoptosis by reactive oxygen species 
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crystallized, collected data and solved the structure of PutA86-630 inactivated with 
N-Propargylglycine. This chapter is taken from Srivastava et. al. Biochemistry 
(2010) 49 (3): 560–569. 
 12 
ABSTRACT	  
Proline utilization A (PutA) from Escherichia coli is a flavoprotein that has mutually 
exclusive roles as a transcriptional repressor of the put regulon and a membrane-
associated enzyme that catalyzes the oxidation of proline to glutamate.  Previous studies 
have shown that the binding of proline in the proline dehydrogenase (PRODH) active site 
and subsequent reduction of the FAD trigger global conformational changes that enhance 
PutA-membrane affinity. These events cause PutA to switch from its repressor to 
enzymatic role, but the mechanism by which this signal is propagated from the active site 
to the distal membrane-binding domain is largely unknown.  Here, it is shown that N-
propargylglycine irreversibly inactivates PutA by covalently linking the flavin N(5) atom 
to the ε-amino of Lys329.  Furthermore, inactivation locks PutA into a conformation that 
may mimic the proline reduced, membrane-associated form.  The 2.15 Å resolution 
structure of the inactivated PRODH domain suggests that the initial events involved in 
broadcasting the reduced flavin state to the distal membrane binding domain include 
major reorganization of the flavin ribityl chain, severe (35 degree) butterfly bending of 
the isoalloxazine ring, and disruption of an electrostatic network involving the flavin 
N(5), Arg431, and Asp370.  The structure also provides information about 
conformational changes associated with substrate binding.  This analysis suggests that the 
active site is incompletely assembled in the absence of the substrate, and the binding of 
proline draws together conserved residues in helix 8 and the β1-αl loop to complete the 
active site. 
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Introduction:	  	  
The oxidative conversion of proline to glutamate requires the coupled activities of 
proline dehydrogenase (PRODH) and ∆1-­‐pyrroline-5-carboxylate (P5C) dehydrogenase 
(P5CDH) (Scheme 1). In some bacteria, these activities are combined in a single 
polypeptide known as proline utilization A (PutA).  The polypeptide chain lengths of 
PutAs exceed 1000 residues, with the PRODH and P5CDH domains appearing in the N-
terminal and C-terminal halves of the protein, respectively (1, 2).  Some PutAs, including 
Escherichia coli PutA, also serve as transcriptional repressors of the put regulon, which 
comprises the divergently transcribed genes encoding PutA and the high-affinity 
Na+/proline transporter, PutP, plus an intervening 419-bp control DNA region (1, 3).  
PutA represses transcription of putA and putP by recognizing, via an N-terminal ribbon-
helix-helix domain, a consensus binding sequence that appears at five different locations 
in the put control DNA region.  In the absence of proline, PutA occupies the five operator 
sites, thereby blocking transcription of the put genes (3). In the presence of proline, PutA 
associates with the membrane where it couples the oxidation of proline to P5C with 
reduction of the electron transport chain (Scheme 1). Following the nonenzymatic 
hydrolysis of P5C, the P5CDH domain catalyzes the	  NAD+-­‐dependent	  oxidation	  of	  γ-
glutamate semialdehyde	  to	  glutamate	  (Scheme	  1)	  (4-­6).	  Thus,	  the	  association	  of	  PutA 
with the inner membrane is not only essential for efficient catalytic turnover, but also 
increases expression of putA and putP by preventing PutA from engaging its operator 
sites in the put control DNA region (1).   
The process by which PutA is transformed from a DNA-bound repressor to a 
membrane-associated enzyme, known as functional switching, involves conformational 
changes triggered by proline binding and reduction of the flavin cofactor (1, 7-9). 
Recently, conformational changes in the FAD were deduced from a structure of the 
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dithionite-reduced E. coli PutA PRODH domain with hyposulfite bound in the proline 
binding site (7).  Upon reduction, the FAD was observed to adopt a new conformation 
characterized by a significant “butterfly” bend (22o) of the isoalloxazine ring and rotation 
of the 2´-OH group of the ribityl chain resulting in formation of a new hydrogen bond 
between the 2´-OH and the FAD N(1) atom (7). The 2´-OH group of the FAD was 
subsequently demonstrated to act as a redox-sensitive toggle switch that helps control 
association of PutA with the membrane (7).   
A second key interaction involves the FAD N(5) atom and Arg431. Arg431 is 
strategically placed within hydrogen bonding distance to the flavin N(5) and is thus 
potentially able to sense changes in electron density across the N(1)-N(5) enediamine 
system attendant to FAD reduction.  Indeed, mutation of Arg431 to Met, or replacement 
of FAD with 5-deaza-FAD, abrogated the ability of proline to activate binding of PutA to 
the membrane (7). Thus, Arg431 was proposed to have an important role in transmitting 
redox signals out of the FAD active site (7), although the dithionite-reduced enzyme 
structure did not indicate any movement of this residue.  
The conformational changes in the FAD deduced from the structure of the dithionite-
reduced PRODH domain (bending of the isoalloxazine ring and rotation of the 2'-OH) 
presumably represent the initial step in transmission of the flavin redox status to a remote 
membrane-binding domain.  Signal transmission likely involves Arg431, but other 
residues important for broadcasting the flavin redox state remain largely unknown. 
Here, we have used mechanism-based inactivation of E. coli PutA by N-
propargylglycine (PPG, 1 in Scheme 2) to elicit conformational changes similar to those 
involved in functional switching.   This work was motivated by our recent study of the 
inactivation of PRODH from Thermus thermophilus (TtPRODH) by PPG (10).  
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TtPRODH is a 307-residue monofunctional PRODH that has 27 % sequence identity to 
residues 235 - 569 of the 1320-residue E. coli PutA protein.  The crystal structure of 
PPG-inactivated TtPRODH revealed a 3-carbon link between the ε–amine of Lys99 and 
the N(5) of FAD.  In one scenario, the mechanism of inactivation is initiated by the 
oxidation of PPG to N-propargyliminoglycine (2 in Scheme 2) and concomitant reduction 
of the FAD.   It is proposed that attack of 2 by the N(5) of the reduced flavin, 
rearrangement of a putative allenic species (3) to an imminium intermediate (4), and 
nucleophilic attack by an active site lysine residue (Lys99) on the imminium intermediate 
lead to the covalent FAD-Lys99 adduct (5).  As a result, the enzyme is, effectively, 
locked into the reduced state. Sequence alignments show that Lys99 is highly conserved 
among monofunctional PRODHs and PutAs, with Lys329 being the corresponding 
residue in E. coli PutA. Since PPG locks TtPRODH in the reduced state, we investigated 
the possibility of using PPG to stabilize the reduced conformation of PutA in order to 
facilitate examination of this important conformation.  Results of these studies are 
described herein.   
EXPERIMENTAL	  PROCEDURES	  
  Materials. N-propargylglycine (PPG) was synthesized as reported (10). E. coli polar 
lipid extracts, phosphatidylglycerol, and 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine 
were purchased from Avanti Polar Lipids Inc. and used without purification.  Full-length 
E. coli PutA and an E. coli PutA PRODH domain construct containing residues 86-630 
(PutA86-630) were expressed and purified as previously reported (8, 11, 12).  All 
chemicals and buffers were purchased from Fisher Scientific and Sigma-Aldrich, unless 
stated otherwise.  All experiments used Nanopure water.   
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Crystallization. Crystallization experiments were performed with PutA86-630, 
which was purified by Ni-iminodiacetic acid chromatography and HiTrapQ anion 
exchange chromatography as described previously (12). After ion exchange, the protein 
was dialyzed into 50 mM Tris-HCl buffer, 50 mM NaCl, 0.5 mM EDTA, and 5 % 
glycerol at pH 7.5.  The sample was then concentrated to ~12 mg/mL as estimated by the 
bicinchoninic acid method (Pierce kit).  The protein was incubated with PPG in a ratio of 
one mg of enzyme per one mg of PPG (~560 molar excess of PPG) for at least 30 min at 
4 °C.   Crystallization experiments were performed at room temperature using the method 
of vapor diffusion.  Initial crystallization conditions were identified using sitting drops 
and commercially available crystal screen kits.   These experiments revealed promising 
crystals in solutions containing PEG 5000 monomethyl ether, ammonium sulfate, and 2-
(N-morpholino)ethanesulfonic acid (MES) buffer.   Following a few rounds of 
optimization, further improvement was obtained using an additive screen approach in 
which crystal screen reagents served as additive solutions.  The base condition consisted 
of 26 % (w/v) PEG 5000 monomethyl ether, 0.15 M ammonium sulfate, and 0.1 M MES 
buffer at pH 5.8.  Reservoir solutions were created by mixing the base condition and 
crystal screen reagent in the ratio of three parts base condition to one part crystal screen 
solution.  The best results were obtained in hanging drops using Index reagent 82 as the 
additive (0.2 M MgCl2, 0.1 M Bis-Tris buffer, 25 % (w/v) PEG 3350, pH 5.5).  In 
preparation for low-temperature data collection, the crystals were soaked in 22 % (w/v) 
PEG 5000 monomethyl ether, 112.5 mM ammonium sulfate, 50 mM MgCl2, 9 % (w/v) 
PEG 3350, 100 mM MES buffer pH 5.8, and 20 % (v/v) PEG200, picked up with 
Hampton mounting loops and plunged into liquid nitrogen.    
X-ray Diffraction Data Collection, Processing, and Refinement. 
Diffraction data were collected at beamline 4.2.2 of the Advanced Light Source.  The 
data set used for structure determination and refinement consisted of 200 frames collected 
with oscillation width of 0.5° per frame and detector distance of 160 mm. The data were 
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integrated with MOSFLM (13) through the iMosflm graphical interface, and scaled to 
2.15 Å resolution with SCALA (14) using the CCP4i interface (15). The space group is 
I212121 with unit cell dimensions of a = 127.5 Å, b = 133.4 Å, and c = 133.6 Å.  There 
are two molecules in the asymmetric unit, which implies a solvent content of 47 % and 
Vm of 2.3 Å3/Da (16). Data processing statistics are listed in Table 2.1.  We note that this 
crystal form differs from the one used in previous crystallographic studies of the E. coli 
PutA PRODH domain, which has space group of I222 with unit cell dimensions of a = 73 
Å, b = 141 Å, and c = 146 Å and one molecule in the asymmetric unit.   (7, 12, 17-19).  
The structure was solved using molecular replacement as implemented in MOLREP 
(20).  The search model was derived from the coordinates of the E. coli PutA PRODH 
domain complexed with the inhibitor L-tetrahydro-2-furoic acid (THFA, PDB entry 
1TIW, (19)).  The structure was refined with PHENIX (21).  Model building was 
performed with Coot (22).  
The final model includes two protein chains, a covalently modified FAD cofactor 
bound to each protein chain, and 241 water molecules.  Each protein chain includes 
residues 87-137, 258-555, and 561-610.  As with all other structures of the E. coli PutA 
PRODH domain (7, 12, 18, 19), electron density for residues 138-257 is weak, and thus 
these residues were not modeled.  As described in Results, inactivation by PPG induces 
substantial disorder in α8 (residues 545 - 562).  Because of the weak electron density in 
this region of the structure, residues 549 - 555 were modeled as polyalanine, and residues 
556 - 660 were not modeled.  The two protein chains have identical conformations within 
experimental error (root mean square deviation of 0.12 Å for Cα atoms). Likewise, the 
active site structures of the two chains are identical.  Refinement statistics are listed in 
Table 2.1.  
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Spectroscopic and Kinetic Characterizations of the Inactivation of 
Full-Length E. coli PutA.  Spectral changes associated with inactivation of full-
length PutA by PPG were monitored by a Cary-100 spectrophotometer using the 
wavelength range 300-600 nm at 25 °C. The absorbance spectrum of oxidized PutA was 
measured in a quartz cuvette at 10 µM in 50 mM potassium phosphate buffer, pH 7.5 
with 10% glycerol. A quartz cuvette with buffer served as the reference.  A fresh 50 mM 
stock solution of PPG was added to the cuvette at a final concentration of 500 µM of 
PPG. The solution was then briefly mixed by inverting the cuvette. Spectra were 
collected immediately after returning the cuvette to the cuvette holder and at subsequent 
20-s intervals for 0-3 min, 30-s intervals for 3-10 min, 60-s intervals for 10-60 min, and 
120-s intervals for 60-90 min. After PPG treatment, the extent of inactivation exceeded 
95 %. PPG-inactivated PutA was denatured by adding sodium dodecyl sulfate (SDS) to a 
final concentration of 0.2% (in 50 mM sodium phosphate buffer, 10% glycerol, pH 7.5) 
as described elsewhere (23), and the resulting flavin spectrum was recorded. Free FAD 
was then separated from denatured PutA by centrifugation using a 10-kDa cut-off 
membrane. The molar extinction coefficients for the flavin compounds with maximum 
absorbance at 378 and 397 nm were estimated using the flavin concentration determined 
for native PutA (ε451= 12700 M-1 cm-1) prior to inactivation. 
The kinetic parameters for PRODH activity of full-length PutA were determined as 
described previously for TtPRODH (10). Accordingly, a fresh 50 mM stock solution of 
PPG dissolved in 50 mM potassium phosphate buffer, pH = 7.5, 10% glycerol, was 
prepared. E. coli PutA (5 µM) was incubated at 25 °C with PPG at concentrations of 
0.25, 0.5, 0.75, 1.0, and 2.5 mM. Aliquots were removed at 15-min intervals over a 
period of 120 min and assayed at 25 °C using a previously described PRODH assay 
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based on the reduction of dichlorophenolindophenol with L-proline (80 mM) as the 
substrate. Inactivation parameters were estimated using the standard method of extracting 
half-lives from plots of the natural logarithm of activity versus time and making a Kitz 
and Wilson replot (24, 25). 
Conformational Changes of Full-Length PutA Accompanied by N-
propargylglycine Inactivation.  Limited proteolysis of full-length PutA by 
chymotrypsin was performed as previously described with the following modifications 
(26). In all digests, PutA was pre-incubated with 5 mM proline or 5 mM THFA, for 5 min 
prior to adding chymotrypsin except for PPG, which was incubated with PutA for 30 min. 
Proline and THFA were dissolved in 50 mM potassium phosphate buffer (pH 7.5). PutA 
(1 mg/mL) was then digested with chymotrypsin (10 µg/mL) for 1 h at 25 °C in 50 mM 
potassium phosphate buffer (pH 7.5) containing 10% glycerol.  The reactions were 
stopped by adding phenylmethylsulfonyl fluoride (2 mM final concentration) and hot 
SDS-PAGE sample buffer at a 1:2 (v/v) ratio of SDS buffer to sample. The samples (7.5 
µg each) were analyzed by SDS-PAGE using 8% acrylamide separating gels. As a 
control, oxidized PutA (2.5 µg) without digestion was also run on the gel.  Gels were 
visualized after Coomassie Blue G-250 staining and imaged using a Bio-Rad Gel Doc 
2000 System. The molecular weight marker was the Precision Dual Color reagent (Bio-
Rad).  
Assays of Full-Length PutA Binding to E. coli Polar Lipids. The 
binding buffer used in these experiments consisted of 10 mM N-(2-
hydroxyethyl)piperazine-N'-2-ethanesulfonic acid containing 150 mM NaCl at pH 7.4 
(HEPES-N buffer). E. coli polar lipid vesicles were prepared as previously described 
using a LiposoFast microextruder with a 100 nm polycarbonate filter at a final 
concentration of 5 mg/ml (8). After pre-incubation of full-length PutA (0.25 mg/ml) with 
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proline (5 mM, 5 min), THFA (5 mM, 5 min), or PPG (5 mM, 30 min) at 25 °C in 150 
mM HEPES-N buffer, the freshly prepared E. coli polar lipid vesicles were added to the 
reaction mixtures to a final concentration of 0.8 mg/mL and incubated at room 
temperature for 1 h with slow rotation. The lipid-bound fraction was then separated from 
the solution phase using an air-driven ultracentrifuge (Airfuge, Beckman) at the 
maximum speed as previously described (27). The supernatant (soluble phase) was 
removed and denatured with SDS sample buffer and labeled as soluble fractions. The 
lipid pellet was resuspended in an equal volume of HEPES-N buffer, denatured with SDS 
sample buffer and labeled as lipid fraction.  Non-specific sedimentation of the PutA 
proteins was not observed in the absence of the lipids.  All the soluble and lipid fractions 
were analyzed with 10 % SDS-polyacrylamide gels, which were stained with Coomassie 
Blue G-250. Quantitative analysis of gels was performed with a Bio-Rad Gel Doc 2000 
System. 
 
RESULTS	  
Spectral Analysis of the Inactivation of Full-Length E. coli PutA by 
PPG.  Similar to that observed with TtPRODH, PPG inactivates full-length E. coli PutA 
with a concomitant spectral change (Figure 2.1A). The absorption spectrum of PutA-
bound FAD decreases at 451 nm after the addition of PPG. Coinciding with the decrease 
at 451 nm is a dramatic increase in absorbance at 378 nm (ε ~ 20800 M-1 cm-1).  The 
decrease at 451 nm indicates that the FAD is fully reduced, similar to reduction of the 
flavin by sodium dithionite or the substrate proline. The significant increase at 378 nm, 
which is not observed with proline or dithionite, suggests a new reduced flavin species is 
formed. The new species is most likely the Lys329-FAD covalent adduct shown in 
Scheme 2 (5).  Formation of this adduct was confirmed by X-ray crystallography (vide 
infra).  
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The covalently modified flavin could be separated from the inactivated enzyme by 
treating PPG-inactivated PutA with a 0.2% SDS solution and isolating the flavin 
component by membrane filtration. The isolated flavin exhibits a strong absorbance 
maximum at 397 nm (ε ~ 22750 M-1 cm-1) (Figure 2.1B, dotted curve), which is similar to 
the spectrum of PPG-inactivated PutA (Figure 2.1B, dashed curve) and distinctly 
different from the spectrum of oxidized PutA (Figure 2.1B, solid curve).  This result 
suggests that the isolated flavin is covalently modified, albeit separated from the enzyme.  
Presumably, the Schiff base in (5) of Scheme 3 undergoes hydrolysis to produce (6) of 
Scheme 3 and the free enzyme as a result of treatment with the SDS buffer. 
Kinetic Analysis of the Inactivation of Full-Length E. coli PutA by 
PPG. The inactivation of full-length PutA by PPG was monitored in a time and 
concentration-dependent manner, as shown in Figure 2.2.  Inactivation profiles of PutA 
by five different PPG concentrations were used to estimate inactivation parameters.  The 
standard method of extracting half-lives from plots of the natural logarithm of activity 
versus time was used to construct a Kitz and Wilson replot (Figure 2.2, inset).  Note that 
the Kitz and Wilson replot intersects the ordinate above the origin, which suggests that inactivation	  proceeds	  with	   saturation,	   i.e.,	   that	   a	  dissociable complex forms prior to 
inactivation (25). This complex of enzyme and PPG is analogous to the binding of 
enzyme and substrate in the E•S complex.  The estimated values for kinact and KI are 0.13 
min-1 and 1.5 mM, respectively. 
Structural Characterization of the Enzyme-FAD Adduct. The structure of 
an E. coli PutA PRODH domain construct (PutA86-630) inactivated by PPG was solved 
to confirm formation of a Lys-FAD covalent adduct, i.e., (5) in Scheme 2. The structure 
was determined at 2.15 Å resolution using molecular replacement (Table 2.1).  As 
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expected, the enzyme displays the distorted (βα)8 barrel fold characteristic of the 
PRODH family (Figure 2.3).  The FAD cofactor is bound at the C-termini of the strands 
of the barrel, with the re face of the isoalloxazine packed against strands 4-6 of the barrel. 
 Electron density maps clearly indicated that the flavin is covalently modified by PPG 
(Figure 2.4).  Inactivation with PPG results in covalent attachment of Lys329 to the flavin 
N(5) via a three-carbon linkage (Figure 2.4A).  Also, the flavin isoalloxazine ring is 
distinctly nonplanar, being bent by about 35° around the N(5)-N(10) axis (Figure 2.4B).  
Such deviations from planarity are referred to as "butterfly" conformations and are 
associated with reduced states of the flavin.  We note that the isoalloxazine ring of the 
dithionite-reduced enzyme also exhibits a butterfly conformation (bend angle of 22°), and 
the isoalloxazine ring of the oxidized enzyme is planar.  Both the covalent attachment of 
an active site lysine residue to the flavin N(5) and the butterfly conformation were 
observed in PPG-inactivated TtPRODH (10).  
Limited Proteolysis Studies of Full-Length E. coli PutA. As reported 
previously, oxidized, reduced, and inhibited forms of full-length E. coli PutA have unique 
proteolytic fingerprints (26).  Therefore, the PPG-inactivated enzyme was also subjected 
to limited proteolysis using chymotrypsin.  As shown in Figure 2.5, oxidized PutA 
displays major proteolysis bands at 135 kDa and 111 kDa, whereas the proline-reduced 
enzyme displays bands at 119 kDa and 111 kDa.  PutA inhibited by the non-reducing 
proline analog THFA exhibits a predominant band at ~ 90 kDa.   These results are in 
excellent agreement with previous studies (26).  PutA inactivated with PPG displays 
prominent bands at 119 kDa and 111 kDa, a pattern similar to that observed with proline-
reduced PutA.  These results suggest that the global structure of the PPG-inactivated 
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enzyme resembles that of the proline-reduced enzyme, and that PPG and proline trigger 
similar conformational changes in PutA. 
Lipid Associations of PPG-Inactivated Full-Length E. coli PutA.  
Physical lipid binding assays were performed in which full-length PutA was incubated 
with E. coli polar lipid vesicles, and the soluble and lipid bound protein fractions were 
separated by centrifugation.  Results of this assay for the oxidized, proline-reduced, 
THFA-bound, and PPG-inactivated forms of PutA are shown in Figure 2.6.  As expected, 
oxidized PutA is detected almost entirely in the soluble fraction, indicating that it does 
not associate with the lipid vesicles (Figure 2.6A).  The corresponding soluble/lipid 
partitioning ratio is 98%/2% (Figure 2.6B).  In contrast, proline-reduced PutA exhibits a 
soluble/lipid distribution of 35%/65%, indicating that reduction of the FAD by the 
substrate induces a dramatic increase in lipid binding. THFA also increases PutA-lipid 
associations relative to the inhibitor-free, oxidized enzyme, but to a lesser extent than 
proline.  The soluble/lipid ratio for THFA-bound PutA is 57%/43%. These results are 
consistent with surface plasmon resonance studies (8) showing that oxidized PutA 
displays no binding to E. coli polar lipid vesicles, proline induces very tight binding (KD 
< 0.01 nM), and THFA stimulates moderately high binding  (KD = 34 nM).  PPG-
inactivated PutA displays a soluble/lipid ratio of 34%/66%, which is comparable to that 
of the proline-reduced enzyme (Figure 2.6B). These results suggest that PPG causes 
PutA-lipid associations that are similar to those induced by proline. 
Comparison to Other PRODH Structures. Since PPG mimics the effects of 
proline on PutA conformation and PutA lipid binding, the structure of PPG-inactivated 
PutA86-630 was compared to other PutA PRODH structures to gain insight into 
conformational changes involved in functional switching.  Also, because this structure is 
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the only one of a PutA PRODH domain without a ligand occupying the proline binding 
site, such a comparison potentially provides clues about conformational changes 
associated with substrate binding.  The relevant structures in the PDB are those of 
oxidized PutA86-669 (residues 86-669 of E. coli PutA) complexed with the proline 
analog THFA (PDB entry 1TIW) and dithionite-reduced PutA86-669 complexed with 
hyposulfite (PDB entry 2FZM).  
The structure of PPG-inactivated PutA86-630 reveals a new conformation for the FAD 
ribityl chain of PutAs (Figure 2.7A).   The 2'-OH is tucked below the pyrimidine ring and 
forms hydrogen bonds with the FAD N(1) and Gly435.  The 3'-OH is rotated 66° from 
the 2'-OH and forms a hydrogen bond with the FAD ribose.  The 4'-OH is oriented trans 
to the 3'-OH and forms a hydrogen bond with a conserved water molecule buried on the 
re side of the FAD.  We note that this ribityl conformation is very similar to that of the 
FAD in oxidized and PPG-inactivated TtPRODH.  
The ribityl hydroxyl groups are arrayed much differently in other structures of the PutA 
PRODH domain (Figures 2.7B, 2.7C).  In the THFA complex, the 2'-OH and 3'-OH 
groups point into the proline binding site where they form hydrogen bonds with Arg556 
and Glu559, respectively (Figure 2.7B).  Both residues are conserved in PutAs and are 
located on α8.  As described below, these critical residues are disordered in the PPG-
inactivated enzyme.  The 4'-OH of the THFA complex is trans to the 3'-OH and forms 
hydrogen bonds with Gly435 and the FAD ribose.  The ribityl chain of the dithionite-
reduced enzyme is identical to that of the THFA complex, except that the 2'-OH sits 
below the flavin N(1), as in the PPG-inactivated enzyme (Figure 2.7C). 
Significant differences are also observed in the protein components of the active site.  
Since the THFA complex and the dithionite-reduced enzyme structures have identical 
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protein conformations, we will restrict the following analysis to a comparison with the 
THFA complex. 
The PPG-inactivated enzyme differs from the other PutA PRODH structures in the 
conformations of two residues near the FAD N(5) atom, Arg431 and Asp370 (Figure 
2.8).  In the THFA complex, Arg431 donates a hydrogen bond to the FAD N(5)  (3.1 Å) 
and forms an ion pair with Asp370 (also 3.1 Å).   In the PPG-inactivated enzyme, the 
Arg431 - N(5) distance has increased to 4.2 Å, indicating disruption of this key 
interaction.  Furthermore, electron density maps indicated that Asp370 occupies two 
conformations in the PPG-inactivated enzyme (Figure 2.8).  One of these conformations 
corresponds to the one observed in the THFA complex (labeled B in Figure 2.8).  In the 
other conformation (labeled A in Figure 2.8), Asp370 is rotated 180° away from Arg431 
and toward a cluster of glutamate residues located on the surface of the protein (residues 
372, 373, 375).  When Asp370 is in conformation A, the ion pair with Arg431 and 
hydrogen bond with Asn368 are not formed.     
Profound structural differences are also observed in two regions important for proline 
binding, α8 (residues 545-562) and the loop connecting β1 to α1 (residues 287-292).  As 
shown in Figure 2.9, α8 is shifted by 3 Å away from the isoalloxazine ring and 
substantially disordered in the inactivated enzyme.  Electron density in the region 
expected for α8 was quite weak, and although the density allowed the modeling of 
residues 545-555 in an α-helical conformation, residues 549-555 were modeled as 
polyalanine due to a complete absence of density for the side chains.  Furthermore, 
density for residues 556-660 was not apparent, and these residues were omitted entirely 
from the final model (dashed curve in Figure 2.9).  The conformation of the β1 - α1 loop 
is also quite different in the inactivated enzyme. In the PPG-inactivated enzyme, this loop 
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is shifted away from the active site by 4 Å, and the side chain of Glu289 is disordered 
(Figure 2.9).  As a result, the Glu289-Arg555 ion pair, which is observed in all other 
PutA PRODH structures, is broken in the PPG-inactivated enzyme. 
Interestingly, the conformations of α8 and the β1 - α1 loop are reminiscent of those in 
the structure of oxidized TtPRODH (PDB code 2G37, (28)), the only other PRODH 
structure without a ligand bound in the proline binding site.  A comparison of these two 
ligand-free enzymes with the PutA86-669/THFA complex is shown in Figure 2.10.  As in 
PPG-inactivated PutA86-630, α8 of TtPRODH is shifted away from the isoalloxazine 
ring, the β1 - α1 loop is withdrawn from the active site, and the conserved ion pair 
(Glu65-Arg288) is broken. Consequently, the active sites of the ligand-free enzymes are 
more open than in the PutA86-669/THFA complex. 
DISCUSSION	  
Mechanism-Based Inactivation of PRODH. Mechanism-based inactivation 
of PRODH was first reported in 1993, but this area of research is nascent nonetheless.  In 
the first study, Trisch et al. found that 4-methylene-L-proline decreased the PRODH 
activity of rat mitochondrial extracts (29).   This area of research lay dormant until our 
report of the inactivation of TtPRODH by PPG in 2008 (10).  In our current study, we 
have further shown that PPG is also an inactivator of the PRODH domain within PutA 
(Figure 2.2).  The kinetic constants for PutA inactivation (kinact = 0.13 min-1, KI = 1.5 
mM) are similar to those of TtPRODH (kinact = 0.43 min-1, KI = 0.8 mM).  Furthermore, 
as with TtPRODH, a dissociable complex is likely formed between PutA and PPG before 
inactivation of the enzyme.  The structures of the PPG-inactivated active sites of PutA 
and TtPRODH are also similar.  In both cases, the flavin is highly bent and covalently 
attached to an active site lysine by a 3-carbon linkage.  These similarities suggest that 
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PutA and TtPRODH share a common mechanism of inactivation by PPG.  The fact that 
PPG inactivates both monofunctional PRODH and PutA suggests that it could be a 
broad-based inactivator of the PRODH family.  A critical test of this idea will be whether 
PPG inactivates monofunctional eukaryotic PRODHs. 
Insight into Conformational Changes of PutA Induced by Substrate 
Binding and Flavin Reduction.  PPG-inactivated E. coli PutA exhibits spectral 
features, proteolysis patterns, and lipid binding properties similar to those of proline-
reduced PutA, implying that PPG and proline induce analogous conformational changes 
in PutA.  Therefore, we suggest that the structure of PPG-inactivated PutA86-630 is 
relevant for understanding the conformational changes involved in functional switching 
of PutA.  In particular, the structure may provide insight into the changes occurring in the 
vicinity of the flavin that help to broadcast the reduced flavin redox state to the distal 
membrane-binding domain.   
The PPG-inactivated enzyme structure may also be relevant for understanding 
conformational changes associated with substrate binding, or equivalently, product 
release, because it is the first one of a PutA PRODH domain without a ligand in the 
proline binding site.  All structures of the oxidized PutA PRODH domain have a 
competitive inhibitor, such as THFA, L-lactate, or acetate bound in the active site.  These 
structures are good models of the Michaelis complex between the oxidized enzyme and 
the substrate, and they show that proline is completely buried in the active site, implying 
that protein conformational changes must accompany substrate binding and product 
release.  The structure of the dithionite-reduced enzyme did not provide insight into such 
conformational changes because a hyposulfite ion, an oxidation product of dithionite, 
occupies the proline site (7).  Because the structure of the empty active site has proven to 
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be elusive, the nature of the conformational changes attendant to substrate binding and 
product release are currently unknown.  
Our analysis of the available structures indicates four regions of interest with regard to 
conformational changes associated with flavin reduction and substrate binding: the FAD 
cofactor, residues near the FAD N(5) atom (Arg431, Asp370), α8, and the β1-αl loop.  
Involvement of the FAD ribityl chain in functional switching is consistent with 
previous biochemical and structural studies.  Membrane-binding studies with mutant 
PutA proteins and PutA reconstituted with 2-deoxy-FAD showed that the 2'-OH group 
acts as a redox-sensitive switch that controls membrane association (7).   The structures 
of the PPG-inactivated and dithionite-reduced enzymes indicate that reduction of the 
flavin induces a 90° rotation in this group.  Additionally, the former structure reveals a 
more substantial reorganization of the ribityl chain involving all three hydroxyl groups 
and a larger distortion of the isoalloxazine ring (butterfly bend).  Although it seems clear 
that the bending of the isoalloxazine ring and rotation of the 2'-OH group are associated 
with functional switching, whether the conformational changes of the 3'-OH and 4'-OH 
groups are consequences of the reduced flavin state or empty proline binding site remain 
to be determined.  
It should be noted that the experimental details of crystal preparation might explain 
some of the differences between the flavin conformations observed in the structures of 
the PPG-inactivated and dithionite-reduced enzymes.   The crystal used to solve the 
former structure was grown from inactivated enzyme, and thus conformational changes 
induced by inactivation were allowed to proceed in solution.  In contrast, the latter 
structure was solved from an oxidized crystal that was soaked in dithionite prior to 
freeze-trapping in liquid nitrogen.  In this case, the preformed crystal lattice likely 
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prohibited extensive conformational changes.  Furthermore, the use of high dithionite 
concentration resulted in a hyposulfite ion binding in the active site.  
The structure of PPG-inactivated PutA86-630 also implicates Arg431 in functional 
switching.  In the THFA complex, Arg431 is poised above the hydride acceptor of the 
FAD and is thus positioned to sense the redox state of the flavin.  The PPG-inactivated 
enzyme structure implies that reduction induces rupture of the N(5)-Arg431 hydrogen 
bond. This result is satisfying because it provides an explanation for previously reported 
results showing that replacement of Arg431 with Met or reconstitution of PutA with 5-
deaza-FAD eliminated reductive activation of PutA-membrane binding (7).  It was 
suggested at that time that Arg431 plays an important role in transmitting redox signals 
out of the PRODH active site that lead to activation of membrane binding and 
transcription of the put regulon, although the structure of the dithionite-reduced enzyme 
did not indicate any change in this residue.  The structure reported here confirms the 
importance of Arg431 in functional switching and suggests that rupture of the N(5)-
Arg431 hydrogen bond might be among the early events that occur in transmitting the 
membrane association signal from the flavin to the membrane-binding domain.   
The PPG-inactivated enzyme structure suggests that Asp370 might also have a role in 
functional switching. The structure shows that flavin reduction weakens the interaction 
between Asp370 and Arg431, allowing the former residue to sample two side chain 
conformational states that are related by a rotation of 180° around χ1.  This result 
suggests the new hypothesis that transmission of the functional switching signal out of 
the active site involves correlated movement of Asp370 and Arg431. 
Finally, the structure of the PPG-inactivated enzyme is unique among PutA PRODH 
domain structures in that helix 8 is substantially unfolded, the conserved Arg555-Glu289 
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ion pair is broken, and the β1-αl loop is withdrawn from the active site.  Consequently, 
the active site is partially disassembled, and the si face of the isoalloxazine ring, i.e., the 
proline binding site, is exposed to solvent.  We suggest that the disassembled active site 
reflects the absence of a bound proline analog, rather than the reduced state of the flavin, 
because α8 and the β1-αl loop are critical for substrate binding.  In particular, Tyr552, 
Arg555, and Arg556 of α8 directly contact the substrate, Glu559 of α8 stabilizes Arg556 
through ion pairing, and Glu289 of the β1-αl loop ion pairs with Arg555 (Figure 2.9).  
Furthermore, the open active site of the PPG-inactivated enzyme bears a striking 
resemblance to that of oxidized TtPRODH, the only other PRODH structure with an 
empty proline binding site (Figure 2.10).   
We thus suggest that the collective structural information on the PutA PRODH domain 
and TtPRODH provides clues about conformational changes attendant to substrate 
binding.  The structures imply that the active site might be incompletely assembled in the 
absence of the substrate, and the binding of proline stabilizes residues of α8 and draws 
the β1-αl loop into the active site in order to connect the loop with α8 via the conserved 
ion pair.  In this scenario, the ion pair might function as a gate that closes and opens in 
response to substrate binding and product release, respectively.  Further experiments are 
needed to test these ideas.  In this regard, structures of the ligand-free, oxidized PutA 
PRODH domain and a monofunctional PRODH complexed with THFA would be 
especially enlightening. 
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Table 2.1: Data collection and refinement statistics for PutA86-630 inactivated with NPPGa 
 
aValues for the outer resolution shell of data are given in parenthesis.  
b5% random test set. 
cCompared to the Engh and Huber parameters (30). 
dThe Ramachandran plot was generated with RAMPAGE (31). 
eMaximum likelihood-based coordinate error reported by PHENIX.
space group I212121 
unit cell lengths (Å) a =  127.5, b = 133.4, c =  133.6 
wavelength (Å) 1.0000 
diffraction resolution (Å) 31.5 – 2.15 (2.25 - 2.15) 
no. of observations 243987 
no. of unique reflections 60418 
redundancy 4.0 (3.3) 
completeness (%) 97.9 (98.9) 
Rmerge(I) 0.094 (0.489) 
Rpim(I) 0.053 (0.303) 
average I/σ 10.3 (3.3) 
Wilson B-factor (Å2) 26 
no. of protein chains 2 
no. of atoms 6480 
no. of protein residues 800 
no. of FAD atoms 106 
no. of water molecules 241 
Rcryst  0.193 (0.250) 
Rfreeb 0.234 (0.292) 
rmsdc  
     bond lengths (Å) 0.006 
     bond angles (deg.) 0.98 
Ramachandran plotd  
     Favored (%) 98.1 
     Allowed (%) 1.9 
     Outliers (%) 0.0 
average B-factors (Å2)  
     protein 34 
     FAD 26 
     modified Lys329 27 
     water 31 
coordinate error (Å)e 0.52 
PDB accession code 3ITG 
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Scheme 2.1 
 
 
 
 
Scheme 2.2 
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Scheme 2.3 
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Figure	  legends	  
 
Figure 2.1. Spectroscopic analysis of the inactivation of full-length E. coli PutA by PPG.  
(A) Flavin spectral changes of E. coli PutA induced by inactivation by PPG.  The 
spectrum of oxidized PutA is represented as the thick curve and has maxima at λ = 451 
nm and 378 nm. Spectra were acquired immediately after adding 500 µM PPG and were 
continually collected for up to 90 min as described in Experimental Procedures.  For 
clarity, only 14 spectra are shown, with the dashed curve indicating the last spectrum. 
Note that the maximum at λ = 451 nm disappears (decreases) and a new maximum 
centered at λ = 378 nm appears (increases) as time advances.  The inset shows the 
absorbance recorded at 451 nm (solid circles) and 378 nm (open circles) during the 90-
min inactivation process.  (B) Denaturation of PPG-inactivated PutA. Spectra are: PutA 
(7.35 µM) before inactivation (solid curve), PutA inactivated with 500 µM PPG for 90 
min (dashed curved), and the flavin species isolated after treatment of PPG-inactivated 
PutA with 0.2 % SDS (dotted curve).  
 
Figure 2.2. Kinetics of PutA inactivation by PPG at 25 °C using a 
dichlorophenolindophenol-based activity assay. The percent activity remaining after 
incubation with PPG is plotted as a function of time for four inactivator concentrations 
(0.25 - 2.5 mM). The inset shows the replot of the half-life of inactivation as a function of 
the reciprocal concentration of PPG. The inactivation parameters obtained from fitting 
are kinact = 0.13 ± 0.05 min−1 and KI = 1.5 ± 0.2 mM. 
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Figure 2.3.  The two views of PPG-inactivated PutA86-630.  Strands and helices are 
colored pink and blue, respectively.  The dashed curves denote disordered segments of 
the polypeptide chain.  The covalent FAD-Lys329 adduct is colored green.  Red coloring 
denotes regions displaying large conformational differences from other PutA PRODH 
domain structures (i.e., α8 and the β1-α1 loop).   
 
Figure 2.4. Electron density maps showing the (A) overall FAD conformation and 
covalent attachment to Lys329 and (B) curvature of the isoalloxazine ring. The cage 
represents a simulated annealing σA-weighted Fo - Fc map contoured at 3σ. Prior to 
calculation of the map, the FAD and side chain of Lys329 were omitted, and simulated 
annealing refinement was performed with PHENIX. 
 
Figure 2.5.  Conformational changes during PutA inactivation by PPG detected by 
limited proteolysis. Purified PutA (1 mg/mL) was incubated for 5 min each with proline 
(5 mM), THFA (5 mM), or for 30 min with PPG (5 mM),  in 50 mM potassium 
phosphate (pH 7.5) followed by digestion with chymotrypsin (10 µg/mL) for 1 h at 23 °C 
. The reactions were quenched with phenylmethylsulfonyl fluoride and hot SDS sample 
buffer after 1 h. After complete denaturation in SDS buffer, 7.5 µg of each digestion was 
loaded onto an 8 % polyacrylamide denaturing gel for analysis. As a control, undigested 
ligand-free PutA was also loaded (2.5 µg). The gel was stained with Coomassie Blue to 
visualize the major products. A molecular mass marker (M) was loaded in the first lane. 
 
Figure 2.6.  Physical binding of PPG-inactivated PutA to E. coli polar lipids.  (A) PutA 
(0.25 mg/ml) was pre-incubated with HEPES-N buffer plus 5 mM proline, 5 mM THFA 
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or 5 mM PPG for 5 min, 5 min or 30 min respectively, and then incubated with freshly 
prepared E. coli polar lipids (0.8 mg/ml) for 1 hr at room temperature. The soluble and 
lipid fractions were then separated by Air-fuge ultracentrifugation, denatured with SDS 
buffer, and analyzed with SDS-PAGE. As a control, an equal amount of denatured PutA 
without treatment was also loaded. (B) Quantitative analysis of PutA bands for the 
soluble (gray bars) and lipid (grey hatched bars) fractions normalized as a percentage of 
total PutA using a Bio-Rad 2000 system. 
 
Figure 2.7.  The FAD conformations observed in three crystal structures of the E. coli 
PutA PRODH domain: (A) PPG-inactivated PutA86-630, (B) oxidized PutA86-669 
complexed with THFA (cyan), and (C) dithionite-reduced PutA86-669.  Helix α8 is 
shown in red for the latter two enzymes; this helix is disordered in PPG-inactivated 
PutA86-630.  Note that the reduced flavins are colored green (panels A, C), whereas the 
oxidized flavin is colored yellow (panel A).   The three flavins are oriented such that the 
AMP moieties are superimposed.  
 
Figure 2.8. Close-up view of structural differences between PPG-inactivated PutA86-630 
(green) and PutA86-669 complexed with THFA (white), highlighting the movements of 
Arg431 and Asp370. The occupancy values for the two conformations of Asp370 in the 
inactivated enzyme are given in parentheses. Orange dashed lines represent hydrogen 
bonds in the PPG-inactivated enzyme.  Black dashed lines represent hydrogen bonds of 
the THFA complex. The cage represents a simulated annealing σA-weighted Fo - Fc map 
contoured at 3σ. Prior to calculation of the map, the side chains of Asp370 and Arg431 
were omitted, and simulated annealing refinement was performed with PHENIX. 
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Figure 2.9. Stereographic view of a superposition of the active sites of PPG-inactivated 
PutA86-630 (green) and PutA86-669 complexed with THFA (white). The THFA ligand 
is colored cyan.  The thin dashed lines indicate hydrogen bonds of the THFA complex.  
The thick dashed curve denotes the disordered section of α8 of the PPG-inactivated 
enzyme.  For clarity, conformation B of Asp370 of the inactivated enzyme has been 
omitted.  
 
Figure 2.10. Stereographic view of a comparison of PPG-inactivated PutA86-630 
(green), PutA86-669 complexed with THFA (white), and TtPRODH (orange).   The 
THFA ligand is colored cyan. The thin dashed lines indicate the Arg555-Glu289 ion pair 
observed in the THFA complex.  Note that Glu289 is disordered in the PPG-inactivated 
enzyme (modeled as Ala), and the corresponding residue of TtPRODH (Glu65) points 
out of the active site and into the solvent.  The thick dashed curve denotes the disordered 
section of α8 of the PPG-inactivated enzyme.  
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Figure 2.1: Spectroscopic analysis of the inactivation of full-length E. coli PutA by PPG. 
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Figure 2.2: Kinetics of PutA inactivation by PPG at 25 °C using a dichlorophenolindophenol-based 
activity assay. 
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Figure 2.3: The two views of PPG-inactivated PutA86-630. 
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Figure 2.4: Electron density maps showing the (A) overall FAD conformation and covalent 
attachment to Lys329 and (B) curvature of the isoalloxazine ring. 
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Figure 2.4: Conformational changes during PutA inactivation by PPG detected by limited 
proteolysis. 
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Figure 2.5: Physical binding of PPG-inactivated PutA to E. coli polar lipids. 
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Figure 2.6: The FAD conformations observed in three crystal structures of the E. coli PutA PRODH 
domain. 
 50 
 
 
 
Figure 2.7: Close-up view of structural differences between PPG-inactivated PutA86-630 and 
PutA86-669 complexed with THFA 
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Figure 2.8: Stereographic view of a superposition of the active sites of PPG-inactivated PutA86-630 
and PutA86-669 complexed with THFA. 
 52 
 
 
 
 
Figure 2.9: Stereographic view of a comparison of PPG-inactivated PutA86-630, PutA86-669 
complexed with THFA, and TtPRODH. 
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Abstract	  
The bifunctional proline catabolic flavoenzyme, proline utilization A (PutA), catalyzes 
the oxidation of proline to glutamate via the sequential activities of FAD-dependent 
proline dehydrogenase (PRODH) and NAD+-dependent Δ1-pyrroline-5-carboxylate 
dehydrogenase (P5CDH) domains.  Although structures for some of the domains of PutA 
are known, a structure for the full-length protein, heretofore, has not been solved.  Here 
we report the 2.1 Å resolution crystal structure of PutA from Bradyrhizobium japonicum, 
along with data from small-angle X-ray scattering, analytical ultracentrifugation, and 
steady-state and rapid-reaction kinetics.  PutA forms a ring-shaped tetramer in solution 
having a diameter of 150 Å.  Within each protomer, the PRODH and P5CDH active sites 
face each other at a distance of 41 Å and are connected by a large, irregularly shaped 
cavity. Kinetics measurements show that glutamate production occurs without a lag 
phase, indicating that the intermediate, Δ1-pyrroline-5-carboxylate, is preferably 
transferred to the P5CDH domain rather than released into the bulk medium.  The 
structural and kinetic data imply that the cavity serves both as a microscopic vessel for 
the hydrolysis of Δ1-pyrroline-5-carboxylate to glutamate semialdehyde and a protected 
conduit for the transport of glutamate semialdehyde to the P5CDH active site.  
 
Author Contribution – Dhiraj Srivastava crystallized, collected data and solved the 
structure of monoclinic crystal form of BjPutA. He also did equilibrium analytical 
ultracentrifugation, small angle X-ray scattering and part of the steady-state 
channeling kinetics. He analyzed the Small Angle X-ray Scattering data with the 
help of Jack Tanner and Greg L. Hura. This chapter is taken from Srivastava et. al. 
Proc. Natl. Acad. Sci. U. S. A. (2010) 107(7):2878-83. 
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Introduction:	  
Oxidation of amino acids is a central part of energy metabolism.  In eukaryotes and 
bacteria, proline is oxidized (or catabolized) to glutamate by the conserved enzymes,  
proline dehydrogenase (PRODH) and Δ1-pyrroline-5-carboxylate (P5C) dehydrogenase 
(Fig. 3.1).    PRODH catalyzes the FAD-dependent oxidation of proline (1 in Fig. 3.1) to 
P5C (2).  The intermediate of proline catabolism, P5C, is hydrolyzed nonenzymatically to 
glutamate γ-semialdehyde (3), which is subsequently oxidized to glutamate (4) by NAD+-
dependent P5C dehydrogenase (P5CDH). In humans, proline oxidation is important for 
cellular redox control, apoptosis, and suppression of cancer (1). Inborn errors in PRODH 
and P5CDH result in types I and II hyperprolinemia disorders (2), and deficiency in 
PRODH activity is thought to be a risk factor for schizophrenia (3).  Moreover, human 
PRODH (known as POX) is a p53-induced enzyme that plays a crucial role in apoptosis 
by serving as a proline-dependent, superoxide generator (1).  Other organisms have 
evolved the ability to harness energy almost exclusively from proline under certain 
circumstances.  Examples include Helicobacter pylori in the human gut (4, 5), procyclic 
trypanosomes in the midgut of insects (6, 7), and the tsetse fly during flight (8, 9). 
Intriguingly, whereas PRODH and P5CDH are separate enzymes in eukaryotes and 
some bacteria, they are fused into a single polypeptide chain in other bacteria. The fused 
enzymes, known as proline utilization A, or PutA, are membrane-associated proteins 
containing 1000-1300 amino acid residues, with the PRODH and P5CDH domains 
located in the N- and C-terminal halves of the polypeptide chain, respectively (10, 11).  
Some PutAs, such those from Escherichia coli (EcPutA) and Salmonella typhimurium, 
also have a regulatory function.  These "trifunctional" PutAs repress transcription of the 
put regulon, which contains the genes for PutA and the proline transporter PutP.   The 
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DNA-binding domain of trifunctional PutAs is a ribbon-helix-helix domain located in the 
N-terminal 50 residues (12-14).   
PutAs have proven to be challenging structural biology targets.  The first structures of 
PutA domains appeared over two decades after Ratzkin and Roth's discovery that 
PRODH and P5CDH were encoded by a single gene in S. typhimurium (15).  These 
include crystal structures of the PRODH (16-19) and DNA-binding (13, 14) domains of 
EcPutA, and a solution structure of the DNA-binding domain of Pseudomonas putida 
PutA (20).  
Whereas the domain structures have informed us about the individual functions of 
PutA, they have not provided insight into how PutAs coordinate multiple functions.  Here 
we report the first crystal structure of a full-length bifunctional PutA.  The structure and 
accompanying kinetic data indicate that P5C undergoes hydrolysis to glutamate 
semialdehyde en route to the P5CDH domain without leaving the confines of the protein. 
 
Results	  
Tertiary Structure.  Several PutAs were screened for crystallizability, which 
eventually led us to focus structure determination efforts on the 999-residue PutA from 
Bradyrhizobium japonicum (BjPutA).  The structure of BjPutA was solved using 
anomalous dispersion diffraction data collected from hexagonal crystals of the Se-Met 
derivative (Table S1) and was subsequently refined to 2.1 Å resolution using native 
diffraction data collected from a centered monoclinic crystal (Table 3.1).  
The protomer consists of the two catalytic domains plus three smaller, ancillary 
domains denoted N-terminal arm, α-helix bundle, and linker (Fig. 3.2A).  The 
asymmetric unit of the C2 crystal form contains two protomers, which form a U-shaped 
 58 
dimer having dimensions of 150 Å x 70 Å x 80 Å  (Fig. 3.2B). The polypeptide chain 
begins with a 51-residue arm-like extension that traverses ~100 Å as it wraps around the 
PRODH domain (Fig. 3.2A, yellow).  The arm is followed by the α-helix bundle domain, 
which comprises six tightly packed α-helices (Fig. 3.2A, green) and contacts both 
catalytic domains.  The PRODH and P5CDH domains follow the α-helix bundle and are 
separated by an 83-residue linker. 
The PRODH domain resembles that of EcPutA in both the overall fold and details of 
the active site.  This domain has a distorted (βα)8 barrel fold (Fig. 3.2, magenta strands, 
cyan helices), which is considered to be diagnostic of the PRODH family (21).   The 
FAD cofactor is bound noncovalently at the C-termini of the strands (Figs. 3.2A, 3.2B).  
The re face packs tightly against strands 4 - 6 of the barrel, allowing proline to bind at the 
si face (Fig. S1).  Residues near the isoalloxazine and proline-binding site are highly 
conserved in PutAs, and many of these residues have similar conformations in BjPutA 
and EcPutA (Fig. S2A).  BjPutA and EcPutA also have identical FAD conformations 
(Fig. S2A).  Finally, there appears to be a sulfate ion bound in the active site.  
Comparison to the structure of the EcPutA PRODH domain complexed with the proline 
analog L-tetrahydro-2-furoic acid indicates that the sulfate ion occupies the binding site 
for the substrate carboxylate group (Fig. S2A). 
The P5CDH domain (Fig. 3.2A, red) is similar to other aldehyde dehydrogenases (22, 
23).  It has two lobes, one that binds NAD+ using a non-classical Rossmann fold and 
another that furnishes catalytic Cys792.  In addition to the two lobes, there is a β-strand 
substructure protruding from the Rossmann fold sub-domain (β-flap, residues 628 - 646, 
977 - 989, see Fig. 3.2A).  The β-flap stabilizes the U-shaped dimer by forming an 
intermolecular β-sheet interaction with the P5CDH domain of the other protomer (Fig. 
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3.2C).  As with the PRODH active site, there is a sulfate ion bound in the P5CDH active 
site.  Comparison with the structure of the monofunctional P5CDH from Thermus 
thermophilus shows that the sulfate ion occupies the binding site for the carboxylate 
group of the substrate glutamate semialdehyde (Fig. S2B).  
 
Quaternary Structure. The oligomeric state of BjPutA in solution was examined by 
analytical ultracentrifugation.  Data from eighteen parallel sedimentation equilibrium 
experiments were fit globally to a single-species model, enabling simultaneous estimation 
of the partial specific volume and molecular weight (Fig. S3).  The best-fit values are 
0.772 mL/g (0.767 - 0.777 mL/g) and 442 kDa (428 - 455 kDa). The partial specific 
volume is significantly larger than the value of 0.74 mL/g calculated from the sequence, 
which is consistent with the observation of a large solvent-filled cavity inside the protein 
(vide infra). The estimated molecular weight is within 3 % of the theoretical molecular 
weight of a tetramer of 430 kDa.  
Small-angle X-ray scattering (SAXS) was used to determine the arrangement of 
protomers within the tetramer.  A typical SAXS profile is shown in Fig. 3.3A (black solid 
curve).  Guinier analysis suggested a radius of gyration of 56 Å.  Calculations of the pair 
distribution function yielded estimates for the radius of gyration and the maximum 
particle dimension of 51 Å and 140 Å, respectively. Shape reconstructions calculated 
with GASBOR (24) indicated that BjPutA forms a ring-shaped particle in solution (Fig. 
3.3A, inset).   
The C2 lattice was inspected to identify a tetramer of BjPutA having the size and 
shape of the SAXS reconstruction.  Such an assembly could be built by applying the two-
fold crystallographic symmetry transformation (-x,y,-z-1) to the U-shaped dimer of the 
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asymmetric unit (Figs. 3.3B, S4).  Further validation of this particular tetramer as the one 
formed in solution was obtained from calculations of the scattering curve from atomic 
models using CRYSOL (25).   The curve calculated from the ring-shaped tetramer 
displays satisfactory agreement with the experimental one (Fig. 3.3A, compare red and 
black solid curves).  In contrast, the curves calculated from the U-shaped dimer (Fig. 
3.3A, dashes), and two other tetrameric assemblies that do not form rings (Fig. 3.3A, 
dots), show poor agreement with the experimental data.  Finally, we note that the 
tetrameric ring is also present in lattices of the hexagonal and orthorhombic crystal forms 
of BjPutA. 
The tetramer is a dimer of dimers having 222 symmetry, which can be described by 
three mutually perpendicular two-fold axes, denoted P, Q, and R, intersecting at the 
centroid of the particle (Figs. 3.3B, S4).   We adopt the convention of labeling the four 
chains O, P, Q, and R, such that the P-, Q-, and R-axes transform the O chain into the P, 
Q, and R chains, respectively.  
There are two types of interface in the tetramer, which bury a total of 8360 Å2 of 
surface area. The larger one is generated by rotation around the P-axis (Fig. 3.2B).  This 
interface features the swapped β-flap interaction shown in Fig. 3.2C and is a well-known 
feature of aldehyde dehydrogenases (26).  The other interface of the tetramer is unique to 
BjPutA and contributes 1760 Å2 of interfacial area.  It is generated by rotation around the 
Q-axis and joins two U-shaped dimers to form a ring such that all four β-flaps face the 
hole of the ring  (Fig. 3.3B).  The last helix of the N-terminal arm, the α-helical bundle 
domain, and part of the linker domain form this interface.  
 
Internal Cavity Implies Substrate Channeling.  Within each protomer, the 
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PRODH and P5CDH active sites face each other at a distance of 41 Å.  Between them is 
an irregularly shaped cavity that connects the si face of the isoalloxazine to the catalytic 
cysteine of the P5CDH domain (Figs. 3.2C, 3.4).   The cavity volume was estimated with 
VOIDOO (27) to be 1400 Å3, which is equivalent to about 170 water molecules.  All 
domains except the arm contribute to the cavity (Fig.  3.2C).  The β-flap evidently serves 
as a lid that covers the cavity of the P-related protomer (Figs. 3.2C, 3.2D); analysis with 
the program MOLE (28) indicates potential openings (3 - 5 Å wide) to the bulk medium 
in this region (Fig. 3.2D).  Because the cavity connects the active sites of a protomer, the 
structure implies the potential for substrate channeling within, rather than between, 
protomers.  
The cavity has three sections, corresponding to the two active sites and a large, 
intervening chamber (Fig. 3.4). The middle chamber is 24 Å by 14 Å in its two largest 
dimensions, and 3-7 Å in the third dimension.  It has a volume of about 1325 Å3, which 
represents over 90 % of the total volume of the entire cavity system.  Thus, the middle 
chamber is large enough to accommodate P5C (molecular volume 102 Å3) and glutamate 
semialdehyde (120 Å3).  The active sites connect to the middle chamber via constrictions 
that have widths approximately corresponding to the diameter of water molecule. 
The connection between the PRODH active site and the middle chamber is 
particularly interesting because of its circuitous path (Fig. 3.4).  It runs down the ribityl 
chain of the FAD and then passes over a potential opening to the bulk medium and under 
the side chain of Arg456 before connecting to the middle chamber.  A more direct path 
into the middle chamber appears to be blocked by the ion-pairing residues Arg456 and 
Glu197.  We note that both residues are identically conserved in PutAs, and Arg456 plays 
an essential role in substrate binding by forming a critical ionic interaction with the 
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carboxylate of the substrate.   
Finally, the walls of the cavity are highly ionic, and thus the cavity itself is very 
hydrophilic.  The cavity walls are lined with twelve arginine, three lysine, ten glutamate, 
and seven aspartate residues, which are represented by the blue (Arg, Lys) and red (Gly, 
Asp) patches in Fig. 3.4.  
 
Kinetic Evidence for Substrate Channeling.  Kinetic measurements were performed to 
explore the possibility of substrate channeling.  The results of a P5C trapping assay are 
shown in Fig. 3.5A.  The trapping experiment uses an excess of o-aminobenzaldehyde (o-
AB), which forms a yellow complex with P5C (29).  In the absence of NAD+, formation 
of the o-AB-P5C complex is evident, indicating that P5C is released into bulk solvent.  In 
contrast, with NAD+ present (0.2 mM), formation of the o-AB-P5C complex is 
significantly diminished, clearly showing that P5C is not released to an appreciable 
extent from the functional enzyme. 
The time-dependence of NADH production from proline was measured to see 
whether a lag phase was present.  NADH is generated by wild type BjPutA at a linear rate 
without an apparent lag phase (Fig. 3.5B, solid curve), which is consistent with substrate 
channeling.  This assay was repeated using an equimolar mixture of BjPutA monofunctional 
variants R456M and C792A as a non-channeling control.  PRODH activity is disabled in 
R456M, but the P5CDH activity is identical to that of the native enzyme (Table S2).  
Conversely, the C792A mutation abolishes P5CDH activity but does not affect PRODH 
activity.  If channeling occurs within the protomer, as suggested by the structure, an 
equimolar mixture of R456M and C792A should not exhibit the kinetic hallmarks of 
channeling.  As shown in Fig. 3.5B (dashed curve), a lag phase of approximately 8 min was 
observed for the mixture of monofunctional variants.  The lag in NADH production is 
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interpreted as the time required for a steady-state level of P5C to accumulate in solution (30).  
The substantial difference between the native enzyme and the non-channeling control in this 
assay is consistent with the hypothesis that substrate channeling occurs in BjPutA.  
Rapid-reaction kinetic measurements were also performed.  BjPutA, proline, and NAD+ 
were rapidly mixed, and the absorbance spectra of the FAD cofactor and NADH product 
were recorded using a stopped-flow instrument. For the non-channeling control, reduction of 
FAD is observed, but no change in absorbance at 340 nm occurs, i.e., NADH is not produced 
(Fig. 3.5C).    In contrast, for the native enzyme, NADH is generated following FAD 
reduction (Fig. 3.5D). The fact that NADH is produced in a time during which no NADH is 
generated by the non-channeling control suggests that channeling occurs.  
 
Discussion	  
The BjPutA structure reveals, for the first time, the architecture of a PutA protein.  
The most significant result is that the two active sites are separated by 41 Å and oriented 
so that the exit path of the PRODH active site faces the substrate entrance tunnel of the 
P5CDH active site.   The cavity connecting the two active sites strongly suggests the 
possibility of substrate channeling within the protomer, which is supported by kinetic 
measurements.  
Although substrate channeling is not unique to PutA, some aspects of channeling in 
PutA are different from other bifunctional enzymes.  In particular, the irregular shape of 
the cavity is rather different from the tunnels that channel indole and ammonia in 
tryptophan synthase and carbamoyl phosphate synthetase (31, 32).  The PutA cavity 
better resembles that of dimethylglycine oxidase, which is also a flavoenzyme that 
channels an imine intermediate (33, 34).  
The demonstration of substrate channeling in BjPutA is consistent with kinetic data 
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reported by Surber and Maloy a decade ago for the trifunctional PutA from S. 
typhimurium (35), the only other study of channeling in PutAs.  As with BjPutA, initial 
production of NADH from proline occurred without a lag phase for S. typhimurium PutA.  
Surber and Maloy also used 14C-labeled proline to show that exogenous P5C does not 
efficiently compete for P5CDH activity in the presence of proline, clear evidence of 
channeling.   The fact that channeling has been demonstrated in both bifunctional and 
trifunctional PutAs suggests that it may be a conserved aspect of PutAs. 
Significantly, this study implies that the P5C produced by PutA is hydrolyzed to 
glutamate semialdehyde within the confines of the protein rather than in the bulk 
medium.  It is tempting to suggest that the hydrolysis reaction occurs in the middle 
chamber, since it is large enough to accommodate glutamate semialdehyde.  The middle 
chamber could also facilitate this reaction by shifting the equilibrium between P5C and 
glutamate semialdehyde to favor the latter species. The equilibrium has a strong pH-
dependence, with the reverse reaction (toward P5C) favored above pH 6.5 (36, 37).  This 
transition point corresponds to the pKa of the pyrrolinium moiety of P5C, indicating that 
protonation of the pyrrolinium favors hydrolysis.  The highly ionic character of the walls 
of the middle chamber could create an electrostatic field inside the cavity that effectively 
increases the pKa of the pyrrolinium moiety, thus favoring the formation of glutamate 
semialdehyde. Future studies involving mutagenesis of charged residues lining the cavity 
will test this hypothesis.  
The structure of the cavity suggests that protein dynamics might play a role in 
channeling.  For example, the conserved Arg456-Glu197 ion pair blocks a direct route 
from the active site to the middle chamber (Fig. 3.4). If P5C formation and concomitant 
reduction of the FAD induce rupture of the ion pair, the PRODH cavity would coalesce 
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with the middle chamber, opening the direct route.  Thus, the ion pair could potentially 
act as a gate that opens and closes in response to product release and substrate binding, 
respectively. This idea is supported by the observation that the conserved ion pair is 
formed in the structure of the EcPutA PRODH domain complexed with THFA (Fig. S2A) 
and broken in the structure of ligand-free monofunctional T. thermophilus PRODH (38).  
We also note that there are several examples of gates and constrictions blocking 
channeling pathways in other bifunctional enzymes (39-42). 
The discovery that BjPutA forms a tetramer was unexpected.  In the only other 
biophysical study of the oligomeric state of a PutA, Brown and Wood concluded that 
EcPutA is an elongated dimer in solution (43), which contrasts the donut shape of 
BjPutA.  An important difference between the two proteins is that EcPutA functions as a 
transcriptional repressor of the put regulon, in addition to being a bifunctional enzyme.  
We previously showed that the repressor domain has a ribbon-helix-helix fold (12-14).  It 
thus appears that bifunctional and trifunctional PutAs differ in quaternary structure, 
which was unanticipated.  This observation raises the question of how the oligomeric 
states of PutAs are related to function.  The relationship seems clear for trifunctional 
PutAs; ribbon-helix-helix domains must dimerize to bind DNA.  In particular, an 
intermolecular β-sheet of the dimer inserts into the major groove of DNA so that side 
chains of the sheet make specific contacts with DNA bases. The significance the U-
shaped dimer of BjPutA is also clear.  The β-flap of one protomer covers the substrate 
channel of the other protomer of the dimer.  On the other hand, the role of the tetramer 
for bifunctional PutAs is, as yet, unknown.  
Finally, our work raises the question of the biological relevance of substrate 
channeling in proline catabolism. Channeling potentially affords the advantages of 
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decreased transit time between enzymes, protection of labile intermediates, and isolation 
of intermediates from competing enzymatic reactions, among others (30-32). Channeling 
in PutA may be particularly beneficial for bacteria that have adapted to use proline as a 
fuel source.  One example is H. pylori, which utilizes proline as a preferred energy source 
in the gut environment, where proline levels in the gastric juice of infected patients are 
10-fold higher compared to uninfected individuals (5, 44).  In this case, channeling likely 
enables efficient use of an available fuel.  Also, channeling segregates the P5C produced 
by proline catabolism from the proline biosynthetic pathway, which also uses P5C as an 
intermediate.  In absence of channeling, a futile cycle of interconversion between proline 
and P5C could occur.  Channeling might also be relevant in humans, because P5C is 
involved in a number of diverse biological functions, including apoptosis, oxidative 
stress, and RNA translation initiation (45-48).  Although human PRODH (POX) and 
P5CDH are distinct (i.e., not fused) mitochondrial enzymes, the fact that the two enzymes 
are fused in PutA, along with the clear demonstration of channeling in PutA, suggests 
that the human enzymes may interact and engage in substrate channeling in order to 
protect P5C from competing biological pathways.      
Materials	  and	  Methods	  
Protein Preparation, Crystallization, and Structure Determination.  
Preparation of native BjPutA and the growth of three crystal forms have been described 
(49).  See SI Text for detailed information regarding the preparation and crystallization of 
selenomethionyl BjPutA, phasing by anomalous dispersion using the hexagonal crystal 
form (Table S1), and molecular replacement calculations for the orthorhombic and C2 
crystal forms.  The structure was refined to 2.1 Å resolution in space group C2 (Table 
3.1).  The final model includes one BjPutA dimer consisting of 1957 of the expected 
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1998 residues, two FAD cofactors, and two NAD+ cofactors.  Chain O includes residues 
1-51, 54-122, and 127-989.  Chain P includes residues 2-50, 55-122, 128-536, and 542-
989.  The missing residues appear in the chain termini, apparently flexible loops (50s 
loop, 120s loop), and the linker between the PRODH and P5CDH domains (chain P).   
 
Equilibrium Analytical Ultracentrifugation.  These experiments were 
performed using a Beckman XL-I Optima analytical ultracentrifuge equipped with an 
An50Ti rotor.  Initial studies indicated that the partial specific volume was larger than the 
value of 0.74 mL/g predicted from the amino acid sequence.  Therefore, the differential 
sedimentation equilibrium method of Edelstein and Schachman was used to 
simultaneously determine the partial specific volume and the molecular weight (50).  
Details of these experiments are provided in SI Text.  
 
Small-Angle X-ray scattering.  Small-angle X-ray scattering (SAXS) experiments 
were performed at beamline 12.3.1 of the Advanced Light Source.  Details of these 
studies can be found in SI Text.  
 
Kinetic Measurements. Steady-state and rapid-reaction methods were used to 
assess substrate channeling, as described in detail in SI Text.  
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Figure	  Legends	  
 
Fig. 3.1. The reactions catalyzed by PRODH and P5CDH.  
 
Fig. 3.2. Structure of BjPutA.  (A) Ribbon drawing of the protomer.  The domains are 
color coded as follows: yellow, N-terminal arm; green α-helix bundle domain; 
cyan/magenta, PRODH domain; slate, linker; and red, P5CDH domain. FAD and NAD+ 
are drawn as sticks in yellow and green, respectively.   The β-flap is colored blue. The 
silver surface represents the internal cavity that connects the two active sites.  (B) The 
dimer of the asymmetric unit, colored as in panel A.  FAD and NAD+ are drawn as 
spheres. (C) Close-up view of the dimer showing the region near the β-flap.  The coloring 
scheme of panel A is used. (D) Surface representation of the β-flap region, shown with 
the same orientation and coloring scheme as in panel C.  
 
Fig. 3.3. SAXS analysis and tetrameric structure of BjPutA.  (A) Experimental and 
simulated scattering profiles.  The solid black curve represents a typical experimental 
scattering curve for BjPutA. The solid red curve represents the profile calculated from the 
ring-shaped tetramer shown in panel B.  The dashed magenta curve was calculated from 
the dimer of the asymmetric unit. The two dotted curves were calculated from other 
tetrameric assemblies that are not shaped like a ring.  The inset shows an ab initio shape 
restoration calculated from the experimental SAXS data using GASBOR.  (B) 
Superposition of the SAXS reconstruction and the crystallographic tetramer. The four 
chains are labeled O (red), P (blue), Q (green), and R (orange). FAD and NAD+ are 
shown in yellow and gray spheres, respectively.    
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Fig. 3.4. Two views of the cavity, differing in a rotation of ~180° around the vertical 
axis.  The cavity is represented as a semi-transparent surface and is colored to indicate the 
locations of positively (blue) and negatively (red) charged residues lining the cavity.  The 
tubes represent pathways identified by the program MOLE.  The green tube guides the 
eye from the PRODH active site to the P5CDH active site.  The orange tubes represent 
possible pathways leading to the bulk medium.   
 
Fig. 3.5. Kinetic evidence for substrate channeling in BjPutA. (A) P5C trapping 
experiments performed in the presence and absence of NAD+.   (B) NADH formation by 
native BjPutA (solid curve) and an equimolar mixture of monofunctional variants R456M 
and C792A (dashed curve).  The dotted curve shows the prediction of a free diffusion 
model for the consecutive PRODH and P5CDH activities in BjPutA. (C) Rapid reaction 
kinetics with the monofunctional BjPutA variants using proline as the substrate.  The 
experiment was performed anaerobically in the absence of an external electron acceptor 
for the reduced flavin.  An equimolar mixture of BjPutA variants C792A and R456M (15 
µM each), NAD+ (0.1 mM), and proline (50 mM) were rapidly mixed and monitored by 
stopped-flow multiwavelength absorption. Curves 1-6: 0.014, 0.042, 0.07, 0.098, 0.18, 
and 3.3 s. Inset: The observed rate of FAD reduction at 450 nm (filled circles) was 
estimated to be 4.6 ± 0.3 s-1 by best-fit of the experimental data. No NADH formation 
was observed at 340 nm (solid line). (D) Rapid reaction kinetics of native BjPutA using 
proline as the substrate. The experiment was performed anaerobically in the absence of 
an external electron acceptor for the reduced flavin.  PutA (30 µM), NAD+ (0.1 mM), and 
proline (50 mM) were rapidly mixed and monitored by stopped-flow multiwavelength 
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absorption. Curves 1-8: 0.013, 0.026, 0.039, 0.052, 0.065, 0.078, 0.18, and 3.3 s. Inset: 
Plot of FAD reduction (circles) and NADH formation (triangles) monitored at 450 nm 
and 340 nm, respectively. The estimated rate constants for reduction of FAD and NAD+ 
are 3.9 ± 0.5 s-1 and 0.7 ± 0.03 s-1, respectively. 
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Figure 3.1: The reactions catalyzed by PRODH and P5CDH. 
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Figure 3.2: Structure of BjPutA 
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Figure 3.3: SAXS analysis and tetrameric structure of BjPutA. 
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Figure 3.4: Two views of the cavity, differing in a rotation of ~180° around the vertical axis. 
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Figure 3.5: Kinetic evidence for substrate channeling in BjPutA. 
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Table 3.1: Data Collection and Refinement Statistics* 
 
Space group C2 
a, b, c, Å 166.8, 195.8, 108.7 
β, ° 121.5 
Resolution, Å 43 – 2.1 (2.2 – 2.1) 
Unique reflections 172549 
Redundancy 3.8 (3.7) 
Completeness, % 99.9 (99.9) 
Rmerge  0.103 (0.412) 
I/σ 12.1 (2.7) 
No. of protein atoms 14647 
No. of FAD and NAD+ atoms 194 
No. of water molecules 795 
Rcryst  0.200 (0.225) 
Rfree† 0.233 (0.281) 
rmsd bond lengths, Å 0.005 
rmsd bond angles, ° 0.86 
Ramachandran – favored 1901 
Ramachandran – allowed 39 
Ramachandran – outliers 3 
Average B for protein, Å2 35 
Average B for FAD, Å2 24 
Average B for NAD+, Å2 32 
Average B for water, Å2 34 
32. Values for the outer resolution shell of data are given in parentheses.  
†5% random test set.  
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SI Text 
Protein Expression, Purification, and Crystallization.  PutA from 
Bradyrhizobium japonicum (BjPutA) was expressed and purified as described previously 
(1).  The selenomethionyl (Se-Met) derivative was expressed using the metabolic 
inhibition method (2).  The derivative was purified like the native enzyme except that all 
buffers used after the immobilized metal ion affinity chromatography step contained 5 
mM DTT. 
Three crystal forms of BjPutA were used in this work: hexagonal, orthorhombic, and 
centered monoclinic (1).   The hexagonal form was grown in PEG and has space group 
P6222 with one molecule in the asymmetric unit.  This crystal form was used for 
experimental phasing using the Se-Met derivative.  The orthorhombic form was also 
grown in PEG. The space group is P212121 with four molecules in the asymmetric unit.  
This crystal form exhibits apparent tetragonal symmetry due to pseudo-merohedral 
twinning.  The orthorhombic crystals diffracted weakly to 2.8 Å resolution (1).  This 
crystal form was useful for verifying the quaternary structure of BjPutA.    The C2 form 
was grown in 2 M ammonium sulfate, has one dimer in the asymmetric unit, and 
diffracted to 2.1 Å resolution.  This crystal form was used for the final refinement. 
 
X-ray Diffraction Data Collection.  The hexagonal crystal form was used for 
experimental phasing.  Data from Se-Met hexagonal crystals were collected at beamline 
19ID of the Advanced Photon Source and processed with HKL2000 (3).  Two crystals 
were used for phasing with the methods of single wavelength anomalous diffraction 
(SAD, crystal 1) and multiwavelength anomalous dispersion (MAD, crystal 2).  For 
crystal 1, a data set was collected at the energy corresponding to the experimentally-
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determined peak of f’’ (λ = 0.97945Å).  The data set consisted of 480 frames collected 
with a detector distance of 240 mm and an oscillation width of 0.5°.   The SAD data set 
was processed to  2.75 Å resolution, was over 20-fold redundant and displayed high 
completeness (Table S1).  For crystal 2, three data sets were collected at energies 
corresponding to the peak of f’’, ascending inflection point, and high energy remote.  
Each consisted of 200 frames collected with a detector distance of 240 mm and an 
oscillation width of 0.5°.   The data sets collected from crystal 2 have high-resolution 
limits of 2.9 – 3.0 Å, greater than 10-fold redundancy, and over 90 % completeness 
(Table S1). 
The C2 form was used for high resolution refinement.  A 2.1 Å resolution data set 
was collected at beamline 4.2.2 of the Advanced Light Source.  The data set consisted of 
720 frames collected with detector distance of 130 mm and oscillation width of 0.25°.  
The reflections were integrated with MOSFLM version 6.2.6 (4) and merged with 
SCALA version 3.2.25 (5).  Data processing statistics are listed in Table 1 of the main 
article.  
 
Experimental Phasing.  Se sites were identified using SOLVE (6).   Sixteen out of 
the eighteen expected sites were found using the SAD data set, and fifteen sites were 
found using the MAD data (Table S1).  The resulting SAD and MAD phase sets had 
figures of merit of 0.40 and 0.47, respectively.  Density modification in RESOLVE (6) 
improved both figures of merit to 0.7.  RESOLVE was also used for automated model 
building.  Using either the SAD or MAD phases after density modification, RESOLVE 
provided a nearly complete backbone trace for the C-terminal half of the protein (P5CDH 
domain).  Density in the N-terminal half of the protein, however, was relatively weak, 
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and the RESOLVE-generated model for the N-terminal half consisted of only seven α-
helices.  In total, RESOLVE correctly identified the amino acid sequence for 75 residues 
using SAD phases and 67 residues using MAD phases.  A composite model was 
constructed using the RESOLVE models from SAD and MAD phasing, and this model 
served as the starting point for several rounds of model building in COOT (7) and 
refinement against the Se-Met peak data sets in CNS (8), PHENIX (9), and REFMAC5 
(10).  Eventually, a partial model containing 726 residues was obtained, which was used 
as the search model to solve the C2 and P212121 crystal forms with molecular 
replacement.  This model included most of the linker and P5CDH domains, but only the 
last helix of the arm domain, none of the α-helix bundle domain, and just over half of the 
PRODH domain.    
 
Molecular Replacement and Refinement.  These calculations were performed 
with MOLREP (11) using a 726-residue model from experimental phasing.  For the C2 
form, a clear solution having two molecules in the asymmetric unit was obtained, which 
had a correlation coefficient of 0.32 and Rcryst of 0.52.  Rigid-body refinement lowered 
Rcryst to 0.45 for reflections to 2.1 Å resolution.  Simulated annealing refinement in 
PHENIX further reduced Rcryst   to 0.37 (Rfree = 0.40) with rmsd bonds of 0.006.  The 
resulting electron density map clearly showed the regions of the structure that were 
problematic in the hexagonal form, such as the FAD cofactor (Fig. S1).   
Using the P212121 data, a clear molecular replacement solution having four molecules 
in the asymmetric unit was obtained, which had a correlation coefficient of 0.33 and Rcryst 
of 0.47 for reflections to 3.5 Å resolution.  The four chains of the asymmetric unit are 
arranged in the ring-shaped assembly shown Fig. S4, providing additional validation of 
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this tetramer as the one formed in solution.  
 
Refinement and Final Model.  The C2 data set was used for refinement to 2.1 Å 
resolution. The model from molecular replacement was extended and improved with 
several rounds of model building in COOT and simulated annealing refinement in 
PHENIX.  The final model includes one BjPutA dimer consisting of 1957 of the expected 
1998 residues, two FAD cofactors, and two NAD+ cofactors (Table 1 of main article).  
Chain O includes residues 1-51, 54-122, and 127-989.  Chain P has residues 2-50, 55-
122, 128-536, and 542-989.  The missing residues appear in the chain termini, apparently 
flexible loops (50s loop, 120s loop) and the linker between the PRODH and P5CDH 
domains  (chain P).  Electron density maps suggested partial occupancy for NAD+, which 
was estimated to be 0.55.  The solvent model includes 795 water molecules, 13 sulfate 
ions, and six glycerol molecules.  The sulfate ions presumably derive from the 
crystallization solution, which contained 2 M ammonium sulfate.  Glycerol was present 
in the protein stock and cryoprotection buffers at 5 % and 25 %, respectively. 
 
Structure analysis.  Several programs and servers were used to analyze structures.  
Protein cavities were identified with VOIDOO (12).  FLOOD (12) was used to estimate 
the number of water molecules accommodated by the cavities and to aid visualization of 
cavities.   Tunnels connecting cavities with bulk solvent were identified with MOLE (13).  
Interfaces were analyzed with the PISA protein interface server (14).   Other analysis 
programs used include CNS (8), COOT (7), and PyMOL (15).  
 
Analytical Ultracentrifugation.  The quaternary structure of BjPutA in solution 
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was analyzed using equilibrium analytical ultracentrifugation.  Data were acquired at 20 
°C using a Beckman XL-I Optima analytical ultracentrifuge equipped with an An50Ti 
rotor.  Initial studies indicated that the partial specific volume (ν ) was larger than the 
value of 0.742 mL/g predicted from the amino acid sequence.  Therefore, the differential 
sedimentation equilibrium method of Edelstein and Schachman was used to 
simultaneously determine ν  and the molecular weight, M (16).  In this method, two 
parallel experiments are performed using protein dialyzed into H2O and D2O solutions.  
The data are fit to an appropriate model that takes into account the increased density of 
the latter solution and the increase in protein mass due to exchange of protons for 
deuterons.  In the present case, satisfactory agreement was obtained using the following 
single-species model: 
 
€ 
c(r) = c(ro)exp
kMω 2(1−ν ρ /k)
2RT r
2 − ro2( )
⎡ 
⎣ 
⎢ 
⎤ 
⎦ 
⎥ + BL                (1) 
 
In this equation, c© is the total protein concentration at radial position r; c(ro) is the 
protein concentration at an arbitrary reference position, ro; M is the molecular weight; ω 
is the radial velocity (rad/s); ν is the partial specific volume of the protein; ρ is the 
solvent density; R is the gas constant; T is the absolute temperature; BL is a baseline 
offset; and k is the ratio of the molecular weight of the protein in the deuterated buffer to 
that in the nondeuterated buffer.  By definition, k is 1.0 for the nondeuterated sample.  
For the deuterated sample (99.8 % D2O), k was estimated to be 1.01616, based on 
analysis of the amino acid sequence using CNS.  
Prior to centrifugation, two identical protein samples having concentrations of 4.3 
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mg/mL were dialyzed into nondeuterated and deuterated buffers containing 50 mM Tris-
HCl, 50 mM NaCl, 0.5 mM EDTA, 5 % glycerol, 0.1 mM FAD, pH 7.5.  For each 
sample, data were collected at three protein concentrations and three rotor speeds (4000 
rpm, 6000 rpm, 8000 rpm) using Rayleigh interference optics.  Measured solvent 
densities were 1.020533 g/mL and 1.120807 g/mL for the two buffers.  The eighteen sets 
of data were fit globally to equation 1 using Origin 8.  Analysis of χ2 using the F-statistic, 
in which M was determined at fixed values of ν , was used to estimate 68 % confidence 
intervals for M and ν . 
 
Small-angle X-ray scattering.  Small angle X-ray scattering (SAXS) experiments 
were performed at beamline 12.3.1 of the Advanced Light Source.  Prior to analysis, 
samples of BjPutA (6 mg/mL) were dialyzed against 50 mM Tris-HCl, 50 mM NaCl, 0.5 
mM EDTA, 5 % glycerol, pH 7.5.  Scattering intensities (I) were measured at three 
protein concentrations (6 mg/mL, 3 mg/mL, 1.5 mg/mL) as a function of the scattering 
vector Q = 4πisinθ/λ, where 2θ is the scattering angle and λ is the wavelength of the 
incident beam.  Exposure times of 0.8 s and 8 s were used.  The scattering curves 
collected from the protein samples were corrected for background scattering using 
intensity data collected from the dialysis buffer.  Forward scattering intensities (I(0)) 
were calculated from Guinier plots (ln I versus Q2) (17) normalized for concentration 
(mass/volume).  The radius of gyration (Rg) was determined by Guinier analysis from 
scattering curves extrapolated to zero concentration using the program PRIMUS (18).   
Composite scattering curves were generated with PRIMUS by scaling and merging 
background-corrected high Q region data from higher concentration samples with low Q 
region zero-extrapolated data. Scattering curves were subjected to indirect Fourier 
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transform using the GNOM program (19) to yield the pair distribution function (P©), 
from which Rg and the maximum particle dimension (Dmax) were estimated. GNOM 
output files were used to calculate ab initio shape reconstructions with DAMMIN (20) 
and GASBOR (21).  At least ten independent reconstructions were performed for each 
data set.  The two programs yielded similar results.  Individual models were aligned by 
SUPCOMB (22) and averaged by DAMAVER (23) to yield the most probable particle 
shape.  Theoretical scattering curves were calculated from atomic coordinates using 
CRYSOL (24). 
 
Kinetic Measurements. Steady-state and rapid-reaction methods were used to 
assess substrate channeling.  To facilitate interpretation of the kinetic data, the assays 
were also performed with a non-channeling control consisting of a solution containing 
equal concentrations of the two BjPutA monofunctional mutant enzymes C792A and 
R456M.  Cys792 is the predicted catalytic Cys residue in the P5CDH domain. Arg456 of 
the PRODH active site is predicted to form a critical ion pair with the carboxylate group 
of the substrate proline (Fig. S2A).  Thus, C792A and R456M are predicted to be 
monofunctional enzymes, with PRODH activity disabled in R456M and P5CDH activity 
disabled in C792A.  These predictions were verified by measuring the PRODH and 
P5CDH activities of the individual mutant enzymes using steady-state assays as 
described for PutA proteins (25, 26).  Kinetic parameters for the native and mutant 
enzymes are listed in Table S2. Measurements were performed in 50 mM potassium 
phosphate buffer (pH 7.5) at 23 oC. PRODH activity was determined by 
proline:ubiquinone oxidoreductase assays using CoQ1 (0.1 mM), 0 – 200 mM proline and 
by following quinone reduction at 278 nm (ε=14.5 mM-1 cm-1). P5CDH activity was 
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monitored by following NAD+ reduction at 340 nm as previously described (26).  The 
effective concentrations of P5C and glutamate semialdehyde at pH 7.5 were estimated 
from the data of Bearne and Wolfenden on the pH dependence of the equilibrium 
between the ring and open chain forms of P5C (27).  The C792A mutant has no P5CDH 
activity, whereas the PRODH activity is unaffected.  Conversely, the R456M mutant has 
no detectable PRODH activity but exhibits P5CDH activity similar to that of native 
BjPutA.  Thus, R456M and C792A are monofunctional variants, as expected.  
 The appearance of the intermediate P5C in the bulk medium was studied using a 
trapping assay based on o-aminobenzaldehyde (o-AB).  P5C forms the yellow 
dihydroquinazolinium complex with o-AB, which is detected by absorbance at λ = 443 
nm (ε = 2900 M-1cm-1 (28)). For this assay, BjPutA (0.19 µM) was incubated with 
proline (40 mM), o-AB (4.0 mM), and inverted membrane vesicles from E. coli (putA- 
strain) in the absence and presence of 0.2 mM NAD+.  The assay buffer contained 50 mM 
phosphate buffer, 10 mM MgCl2, and 25 mM NaCl at pH 7.5.  
Assays designed to detect a lag phase in the progress curve for the production of 
NADH from proline were also performed.  Observation of a lag phase in the progress 
curve would be inconsistent with channeling. The formation of NADH was monitored at 
340 nm in assays performed at 23 °C containing BjPutA (20 µg), proline (40 mM), 
ubiquinone (0.1 mM), and NAD+ (0.2 mM) in a buffer containing 50 mM potassium 
phosphate, 25 mM NaCl, and 10 mM MgCl2 at pH 7.5. Identical assays were performed 
using 20 µg each of the monofunctional BjPutA variants C792A and R456M. Spectral 
interference caused by changes in quinone absorbance at 340 nm was corrected for by 
subtracting progress curves from assays performed under identical conditions in the 
absence of NAD+.   
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The progress curve for two non-interacting PRODH and P5CDH enzymes was 
simulated as described previously for a diffusion model using equation 2 (29).  
  
[NADH] = v1t + (v1/v2)Km(e-v2t/Km -1)  (2) 
In this equation, v1 is the rate (1.6 µM min-1) of PRODH activity under the reaction 
conditions.  The parameters v2 (21 µM min-1) and Km (0.18 mM) are the steady-state 
kinetic parameters Vmax and the Michaelis constant, respectively, for P5CDH activity of 
the R456M mutant. 
 The reaction of proline with BjPutA was also studied by rapid-reaction kinetic 
measurements under single turnover conditions.  BjPutA (28.52 µM, in 50 mM K-
phosphate, 50 mM NaCl, pH 7.5) was preincubated with 0.2 mM NAD+ and then rapidly 
mixed with an equal volume of 80 mM proline in 50 mM potassium phosphate buffer 
(pH 7.5) with 50 mM NaCl.  For the non-channeling control reaction, an equimolar 
mixture of R456M (59.6  µM) and C792A (59.6  µM) (both mutants in 50 mM K-
phosphate, 50 mM NaCl, pH 7.5) was preincubated with 0.2 mM NAD+ and then rapidly 
mixed with an equal volume of 80 mM proline in 50 mM potassium phosphate buffer 
(pH 7.5) with 50 mM NaCl. The final concentrations of the reagents after mixing were 40 
mM proline, 50 mM K-phosphate (pH 7.5), 50 mM NaCl, and 0.1 mM NAD+. The 
enzyme concentrations after mixing were 14.26 µM (native PutA) and 29.8 µM each of 
the monofunctional mutants C792A and R456M. Thus, the concentration of functional 
active sites in the experiment using the native enzyme (14.26 µM PRODH and 14.26 µM 
P5CDH) was similar to that of the non-channeling control experiment (14.9 µM PRODH 
and 14.9 µM P5CDH actives sites from C792A and R456M, respectively).  
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 The reduction reactions of FAD and NAD+ were monitored by stopped-flow 
multiwavelength absorption in the range of 300-700 nm with a Hi-Tech Scientific SF-
61DX2 stopped-flow instrument equipped with a photodiode array detector and 
KinetAsyst software.  Experiments were performed anaerobically in the absence of an 
external electron acceptor for the reduced flavin as follows.  Substrate and BjPutA 
solutions were degassed by repeated cycles of vacuum and flushing with oxygen-
scrubbed nitrogen. Protocatechuate dioxygenase (PCD, 0.05 U/ml) and protocatechuic 
acid (PCA, 100 µM) were then added to the solutions to further remove oxygen and 
maintain anaerobic conditions.  The solutions were transferred to anaerobic syringes 
under a nitrogen atmosphere in a glovebox (30).  The stopped-flow mixing chambers 
were thoroughly washed with anaerobic buffer and incubated overnight with buffer 
containing PCD/PCA prior to the experiments. The temperature of the mixing chamber 
was maintained at 25 °C.  
 The observed rate constants (k1) for FAD reduction (0.2 s-1) and NAD+ reduction 
(0.025 s-1) with native BjPutA were obtained by fitting single exponential equations to 
the absorbance decrease at 451 nm (y = Ae-k1t + C) and increase at 341 nm (y = A(1-e-k1t ) 
) using non-linear least squares regression and SigmaPlot software (Figs. S7A, S7B).  
The concentration of oxidized FAD was calculated at each time point using εox, 451 nm = 
13600 M-1 cm-1 and εred, 451 nm = 100 M-1cm-1 for the oxidized and reduced FAD species, 
respectively. NADH was quantitated using a molar extinction coefficient of 6220 M-1cm-1 
at 341 nm, which is also the isosbestic point for spectral changes that accompany FAD 
reduction.   We note that the observed pseudo first order rate constant of 0.2 s-1 for FAD 
reduction and the calculated second order rate constant of 1753 M-1s-1 for NADH 
formation (kobs/[P5C] = 0.025 s-1/14.26 µM from one turnover of the PRODH active site) 
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are consistent with the apparent turnover rate of NADH formation in steady-state 
channeling assays with native BjPutA under similar conditions (0.12 s-1 and 600 M-1s-1 
(V/Km(P5CDH))) (Fig. 3.5B).  
The observed rate constants (k1) for FAD reduction (0.144 s-1, 90% amplitude) and 
NAD+ reduction (0.0163 s-1) with the equimolar mixture of the two C792A and R456M 
variants were obtained by fitting double exponential equations to the absorbance changes 
at 451 nm (y = Ae-k1t + Be-k2t + C) and 341 nm (y = A(1-e-k1t) + e-k2(t0-t) + C) (Figs. S7C, 
S7D).  At 451 nm the second rate constant k2 represents only 10% of the FAD reduction, 
whereas at 341 nm the second exponential accounts for the observed lag time (~10 sec) 
prior to NADH formation. 
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Figure Legends 
 
Fig. S1. A view of the FAD cofactor, highlighting its location relative to the strands of 
the (βα)8 barrel. The map is a simulated annealing σ A-weighted Fo – Fc omit map 
contoured at 3.0 σ. Prior to map calculation, the flavin was omitted, and simulated 
annealing refinement was performed using PHENIX.  
 
Fig. S2. Stereo views of the two active sites of BjPutA. (A) Superposition of the PRODH 
active sites of BjPutA (green) and EcPutA (white).  The structure of the EcPutA active 
site was determined from a PRODH domain construct containing residues 86-630 of 
EcPutA (PutA86-630, PDB code 1tiw, (31)). The sulfate ion of BjPutA is colored cyan.  
The proline analog L-tetrahydro-2-furoic acid bound to PutA86-630 is colored magenta. 
The FAD cofactors of both enzymes are colored yellow.  The dashed lines represent 
electrostatic interactions in BjPutA (black) and PutA86-630 (orange). (B) Superposition 
of the BjPutA P5CDH active site (green) and the active site of the monofunctional 
P5CDH from T. thermophilus (white, PDB code 2bhq,(32)). The sulfate ion of BjPutA is 
colored cyan.  The bound glutamate of T. thermophilus is colored magenta. The dashed 
lines represent electrostatic interactions in BjPutA (black) and the monofunctional 
P5CDH (orange).  Two conformations are observed for Cys792 of BjPutA, which is due 
to the partial occupancy of NAD+.  
 
Fig. S3. Analytical ultracentrifugation data for BjPutA in non-deuterated (open symbols) 
and deuterated (filled symbols) solvent.   The top panel shows a global fit of 
sedimentation equilibrium data to an ideal single-species model (Equation 1 of SI Text).  
Data were acquired at 4000 (squares), 6000 (circles), and 8000 (triangles) rpm at three 
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nominal loading concentrations of 4.3, 2.2, and 1.1 mg/mL.  The solid lines represent the 
best least-squares fit to an ideal single-species model. Residuals for the optimal fit are 
displayed in the bottom panel. For clarity, vertical offsets have been applied, and only a 
subset of the data points is displayed.  
 
Fig. S4. Orthogonal views of the BjPutA tetramer. (A) Ribbon drawing of the tetramer, 
viewed down the R molecular axis.  The four chains are labeled O (red), P (blue), Q 
(green), and R (orange). FAD and NAD+ are shown in yellow and gray spheres, 
respectively.  (B-D) Superposition of the SAXS reconstruction and the crystallographic 
tetramer, as viewed down the three molecular two-fold axes.  The color coding is the 
same as in panel A. 
 
Fig. S5. Stereographic view of the cavity. The orientation of this figure differs from that 
of Fig. 3.4 by a rotation of ~180° around the vertical axis.   The cavity is represented as a 
semi-transparent surface and is colored to indicate the locations of positively (blue) and 
negatively (red) charged residues lining the cavity.  The tubes represent pathways 
identified by the program MOLE.  The green tube guides the eye from the PRODH active 
site (top) to the P5CDH active site (bottom).  The orange tubes represent possible 
pathways leading to the bulk medium.  
 
Fig. S6. Rapid-reaction kinetic data for native BjPutA (black, left vertical axes) and the 
mixed variants non-channeling control (red, right vertical axes). (A) Progress curves 
showing the time range of 0 – 250 sec. Note the lag in NADH production for the non-
channeling control.  (B) Expansions of the initial regions of the progress curves from 
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panel A.  For the mixed variants [FADox] curve, the concentration of FADox remaining at 
the end of the experiment (16.5 uM) was subtracted from each data point in order to 
facilitate the plotting of [FADox] and [NADH] on the same scale. 
 
Fig. S7. Residual analysis of stopped-flow kinetic data representing (A) reduction of FAD 
in the native enzyme, (B) production of NADH by the native enzyme, (C) reduction of 
FAD in the mixture of monofunctional variants, and (D) production of NADH by the 
mixture of monofunctional variants.  In each panel, the upper plot shows the data points 
(circles) and the best least-squares fit to an exponential model (solid curve), while the 
lower panel shows the residuals for the optimal fit.   
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Figure S1: A view of the FAD cofactor, highlighting its location relative to the strands of the (βα)8 
barrel. 
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Figure S2: Stereo views of the two active sites of BjPutA. 
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Figure S3: Analytical ultracentrifugation data for BjPutA in non-deuterated and deuterated solvent. 
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Figure S4: Orthogonal views of the BjPutA tetramer. 
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Figure S5: Stereographic view of the cavity. 
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Figure S6: Rapid-reaction kinetic data for native BjPutA and the mixed variants non-channeling 
control. 
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Figure S7: Residual analysis of stopped-flow kinetic data. 
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Table S1: Data Collection and Phasing Statistics for Se-Met Derivative of BjPutA 
 Crystal 1 
Peak 
Crystal 2  
Peak 
Crystal 2 
Inflection 
Crystal 2 
Remote 
Beamline APS 19ID APS 19ID APS 19ID APS 19ID 
Space group P6222 P6222 P6222 P6222 
Unit cell parameters  
(Å, degrees) 
a = 142.5    
b = 185.9 
a = 142.1    
b = 185.5 
a = 142.1    
b = 185.5 
a = 142.1    
b = 185.5 
Wavelength (Å) 0.97945 0.97945 0.97962 0.95372 
Diffraction resolution (Å) 50 – 2.75  
(2.85 – 2.75) 
50 – 2.9  
(3.0 – 2.9) 
50 – 2.9  
(3.0 – 2.9) 
50 – 3.0  
(3.1 – 3.0) 
No. of observations 779946 293686 268424 235460 
No. of unique reflections 29719 23556 23406 21158 
Redundancy 26.2 (23.5) 12.5 (12.4) 11.5 (10.9) 11.1 (10.3) 
Completeness (%) 100 (100) 93.6 (95.4) 92.8 (91.6) 92.6 (90.8) 
Rmerge  0.094 (0.450) 0.091 (0.482) 0.079 (0.478) 0.092 (0.450) 
Average I/σ 44.9 (8.6) 24.1 (4.4) 25.3 (4.1) 21.5 (4.0) 
No. Se sites 16 15   
Figure of merit before DM† 0.40 0.47   
Figure of merit after DM‡ 0.70 0.68   
*Values for the outer resolution shell of data are given in parentheses.  
†The figure of merit was calculated using SOLVE before density modification.   
‡The figure of merit was calculated using RESOLVE after density modification. 
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Table S2: Kinetic constants for native BjPutA and monofunctional BjPutA variants 
PRODH Activity P5CDH Activity Overall Pro/Glu 
 Km 
(mM) 
kcat   
(s-1) 
kcat/Km 
(M-1 s-1) 
Km 
(mM) 
kcat 
(s-1) 
kcat/Km 
(M-1 s-1) Km (mM) kcat (s
-1) 
Native 31 ± 6 2.0 ± 0.1 65 
0.20 ± 
0.06 
2.2 
± 
0.7 
11000 24 ± 1 0.5 ± 0.2 
R456M BD* BD BD 0.18 ± 0.04 
1.9 
± 
0.6 
10555 BD BD 
C792A 31 ± 5 1.7 ± 0.1 55 BD BD BD BD BD 
*Below detection limit of assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 113 
Chapter	  4	  –	  Structure	  and	  kinetics	  of	  human	  P5C	  dehydrogenase	  
and	  its	  mutants	  
 
 
Introduction	   – P5C dehydrogenase, also called γ-glutamyl semialdehyde 
dehydrogenase or ALDH4A1, is an aldehyde dehydrogenase, which catalyzes the 
oxidation of γ-glutamyl semialdehyde (Pyrroline-5-carboxylate, P5C) to glutamate with 
concomitant reduction of NAD+ to NADH. P5C is itself a product of oxidation of proline, 
a process catalyzed by proline dehydrogenase.  
 
 
There have been a total of nineteen aldehyde dehydrogenase genes that have been 
identified in humans. Most of the aldehyde dehydrogenases are either dimeric or 
tetrameric (Table 4.1). An exception is ALDH4 (P5C dehydrogenase) which can be 
dimeric (Human and Mice P5C dehydrogenase) or hexameric (Thermus thermophilus 
P5C dehydrogenase and Yeast Put2).  
The oxidation of proline to glutamate is catalyzed by two enzymes, proline 
dehydrogenase (ProDH) and pyrolline-5-carboxylate dehydrogenase (P5CDH). P5C 
dehydrogenase is an aldehyde dehydrogenase and catalyzes the NAD+ dependent 
oxidation of P5C to glutamate. In addition to the degradation of proline, P5C 
dehydrogenase is also involved in the degradation of ornithine1. Ornithine 
aminotransferase catalyzes the interconversion of ornithine and γ-glutamyl semialdehyde. 
The aldehyde dehydrogenase superfamily is classified in 11 separate families and P5C 
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dehydrogenase is a member of the aldehyde dehydrogenase 4 family and is subsequently 
also termed as ALDH4A1.  
In eukaryotes, proline dehydrogenase is associated with the inner mitochondrial 
membrane while P5C dehydrogenase is found in the mitochondrial matrix2. P5C 
dehydrogenase is a non-specific enzyme, which catalyzes the oxidation of widely 
differing substrates ranging from propionaldehyde to adipic semialdehyde3. However 
P5C dehydrogenase attains maximum velocity when P5C is used as the substrate. P5C 
and γ-glutamic semialdehyde is in equilibrium and equilibrium is towards P5C at pH 7.0. 
Considering the effective concentration of γ-glutamyl semialdehyde at pH 7.0, it is about 
8000 times better substrate than acetaldehyde and propionaldehyde, about 30 times better 
than succinic semialdehyde, and about 8-10 times better than glutaric and adipic 
semialdehyde. P5C dehydrogenase follows an ordered bi-bi mechanism where NAD+ 
initially binds to the enzyme followed by γ-glutamyl semialdehyde. After the oxidation of 
γ-glutamyl semialdehyde, glutamate releases from the active site followed by the release 
of NADH4.  
 
The Km for NAD+ is 374 µM and for γ-glutamyl semialdehyde is 68 µM.   Higher 
eukaryotes evolve to have hydroxyproline present in their collagen. As a result, these 
organisms have an additional enzyme for the oxidation of hydroxy-proline to Δ1-
pyrroline-3-hydroxy-5-carboxylate (3-OH-P5C), known as hydroxy-proline 
dehydrogenase. Based on genetic evidence there is only one P5C dehydrogenase that 
 115 
oxidizes both P5C and 3-OH-P5C1. However there is no biochemical evidence supporting 
this hypothesis.   
Deficiency in P5C dehydrogenase enzyme lead to a disease condition called type II 
hyperprolinemia5. Type II hyperprolinemia is a rare autosomal recessive disorder of 
proline catabolism characterized by 10-15 fold increase in plasma proline and increased 
P5C level. A clinical symptom of type II hyperprolinemia is childhood seizures6. Several 
mutations in human P5C dehydrogenase gene has been reported in literature. There is a 
frame shift mutation in codon 7, A7fs(-1), which leads to premature termination of 
translation and absence of P5C dehydrogenase activity.  Effect of mutations P16L, 
S352L, and G521fs(+1) on the activity of P5C dehydrogenase has been studied by 
functional complementation assay in yeast7. P5C dehydrogenase deficient strain of yeast, 
Saccharomyces cerevisiae, expressing S352L and G521fs(+1) mutant of human P5C 
dehydrogenase was failed to grow on medium with proline as sole nitrogen source and 
did not have detectable P5C dehydrogenase activity. However P16L mutant produced 
fully functional P5C dehydrogenase enzyme.   Recently five other mutations in P5C 
dehydrogenase gene have been reported8 that might have an influence on P5C (proline) 
metabolism, though their actual involvement in disease is not clear. These newly 
identified mutations are E277K, G366R, F388L, V470I, and T473A. 
The structure of Thermus thermophilus P5C dehydrogenase has been solved by 
Tahirov et. al. (2005)9. However, the P5C dehydrogenase from Thermus thermophilus is 
only 31% similar to human P5C dehydrogenase and is hexameric. On the other hand 
human P5C dehydrogenase is dimeric.  
In this work, I have solved the structure of human P5C dehydrogenase in two 
different crystal forms, mouse P5C dehydrogenase and Saccharomyces cerevisiae Put2. 
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Structure of human P5C dehydrogenase in hexagonal crystal form, solved at 2.5 Å 
resolution, represents the substrate bound state while structure in monoclinic crystal 
form, which was solved at 1.95 Å, represents the ligand free state of human P5C 
dehydrogenase. The structure of mouse P5C dehydrogenase, which is 95 % similar to 
human P5C dehydrogenase, was solved at 1.3 Å resolution and serve as the high-
resolution model of human P5C dehydrogenase.  Structure of Put2, solved at 1.95 Å 
resolution, together with Thermus thermophilus P5C dehydrogenase helps us in 
understanding the oligomerization of P5C dehydrogenase. We have also done the global 
analysis of mammalian aldehyde dehydrogenase to find out why some aldehyde 
dehydrogenases are dimer while some others are tetramer. We have also compared the 
structure of human P5C dehydrogenase, Mouse P5C dehydrogenase, Put2 and Thermus 
P5C dehydrogenase to find out the reason of Thermus and Put2 being hexameric. 
 In this article we have provided the biochemical evidence of only a single 
enzyme being involved in catalyzing the oxidation of P5C and 3-OH-P5C. Based on 
structure and kinetics, we have tried to explain the effect of mutations on the activity of 
human P5C dehydrogenase and possibly in hyperprolinemia II. The high-resolution 
structure of mouse P5C dehydrogenase allowed us to look into the details of the active 
site and the water mediated hydrogen-bonding network around the active site. This 
structure helped in explaining the effect of the S352L mutation on the activity of human 
P5CDH. The structure of dimeric ALDH4A1 with hexameric TtP5CDH and Put2 and 
other tetrameric aldehyde dehydrogenase were compared to find out the structural basis 
of different oligomeric states in the aldehyde dehydrogenase superfamily.   
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Materials	  and	  Methods	  
A. Cloning, expression, and purification 
1. HsP5CDH –  
 a. Constructs –  
(1) Parent constructs –  
  The gene encoding HsP5CDH (NP_003739) was obtained from ATCC and 
subcloned into pET28a vector as follows. To delete the mitochondrial leader 
sequence, the human P5CDH gene was amplified from residues 18-563 using the 
primer AAGTCACATATGACCGGGGCCGGCCTGCG and 
AAGTCACTCGAGTCACTGCATGTACGCGTAGC as the sense and antisense 
primer respectively. The HsP5CDH gene was cloned between the NdeI and XhoI 
restriction sites of pET28a. S352L, S352A, F388L, V470I and T473A mutants were 
created by the Quick change XLII mutagenesis kit using the following primers –  
S352L Mutation –  
Sense Strand – 5’-CCGCGTGCCTGCGTCTCTACGTGCCGC-3’ 
Antisense Strand- 5’-CGTAGAGACGCAGGCACGCGGAACACTTCTGG-3’ 
S352A Mutation –  
Sense Strand – 5’-CCGCGTGCGCGCGTCTCTACGTGCCGC-3’ 
Antisense Strand- 5’-CGTAGAGACGCGCGCACGCGGAACACTTCTGG-3’ 
F388L Mutation – 
 Sense Strand -   5’-GAGGATTTTGGGACCTTCCTGTCTGCAGTGATTGATGCC-3’ 
Antisense Strand – 5’-GGCATCAATCACTGCAGACAGGAAGGTCCCAAAATCCTC-3’ 
V470I mutation –  
Sense Strand – 5’-AGACGCTGCAGCTGATTGACAGCACCACC-3’ 
AntiSense Strand – 5’-TGGTGCTGTCAATCAGCTGCAGCGTCTCC-3’ 
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T473A Mutation – 
Sense Strand – 5’-GCTGGTTGACAGCGCCACCAGCTATGGCC-3’   
AntiSense Strand – 5’-CATAGCTGGTGGCGCTGTCAACCAGCTGC-3’ 
 
Mutations were verified by DNA sequencing at the DNA core, MU.   
 
(2) Short construct –  
To get a crystal form free of crystallographic contacts involving the N-terminal of 
HsP5CDH, residues 1-33 were deleted from the HsP5CDH gene. The HsP5CDH 
gene was amplified from residues 33-563 using the primer 
AAGTCAGGATCCAACGAGCCCGTCTTAGC and the T7 terminator reverse 
primer and cloned in to the BamHI and XhoI restriction sites of pSV281.  
b. Expression and purification –  
(1) Parent construct 
HsP5CDH and its mutants were transformed in to Bl21(DE3)pLysS competent cells. 
Two liters of LB media, supplemented with 50 µg/l kanamycine, were inoculated 
with 1 % overnight grown starter culture and grown at 370C / 250 rpm until the 
OD600=0.6. The wild type HsP5CDH and all of its mutants, except S352A were 
induced with 50 µM of IPTG for about 20 hours at 220 C/ 200 rpm. HsP5CDH 
S352A was induced with 0.5 mM IPTG at 220 C / 200 rpm for 20 hours. 
The cells were harvested by centrifuging the media at 3500 rpm for 30 minutes in a 
Sorvall SLC 6000 rotor. Cells were resuspended into 20 mM Hepes, 60 mM NaCl, 5 
% glycerol, pH 8.0, quick frozen into liquid nitrogen, and stored at -80° C until 
further purification.  
 119 
Cells were thawed and broken by sonication. Cell debris was cleared from the 
supernatant by centrifuging the cell extract at 16500 rpm for 1 hour in a SS34 rotor. 
The supernatant, free of cell debris, was applied to a HisTrapHP Ni-affinity column, 
equilibrated with buffer A (20 mM Hepes, 300 mM NaCl, 5 % glycerol, pH 8.0). 
The column was washed with buffer A followed by buffer A plus 30 mM 
 midazole. Protein was eluted with buffer A plus 300 mM  midazole and column 
was washed for next round of purification with buffer B (20 mM Hepes, 300 mM 
NaCl, 5 % glycerol, 1 M Imidazole, pH 8.0).      
To prepare the untagged protein, the protein after Ni-affinity purification was 
dialyzed into thrombin cleavage buffer ( 20 mM Tris, 150 mM NaCl, 2.5 mM CaCl2, 
5 % glycerol, pH 8.0). The his-tag was removed by adding 1 unit of thrombin / 4 mg 
of P5CDH and incubating at 40 C for one day. Thrombin and tagged protein was 
removed from untagged protein by passing sample through HiTrap Benzamidine FF 
Affinity Column followed by HisTrap HP Ni-affinity column. Purity of untagged 
protein was evaluated by running SDS-PAGE. Pure protein was dialyzed in to 
precrystallization buffer (50 mM Tris, 50 mM NaCl, 0.5 mM EDTA, 0.5 mM THP, 
5 % glycerol, pH 8.0). 
For the His-tagged protein, eluent after Ni-affinity purification was dialyzed into 50 
mM Tris, 0.5 mM EDTA, 0.5 mM THP, 5 % glycerol, pH 8.0. Sample was loaded 
on to a HiTrap Q anion exchange column. HsP5CDH comes out of the column in the 
flow through. After verifying the purity of the protein by SDS-PAGE, protein was 
dialyzed in to precrystallization buffer. 
(2) Short construct –  
HsP5CDH 33-563 was expressed and purified as the parent construct, except a few 
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minor changes. Induction was done with 0.5 mM IPTG and the His-tag was cleaved 
with TEVP. TEVP and His-tagged protein were removed from untagged protein by 
passing the sample through a HisTrap HP Ni-affinity column. Untagged protein 
eluted with 30 mM Imidazole. Purified HsP5CDH 33-563 was dialyzed in the same 
precrystallization buffer used for parent constructs.  
(3) Se-Met derivative of human P5C dehydrogenase –  
Se-Met derivative of HsP5CDH was prepared by the method of metabolic 
inhibition10. An overnight starter culture was grown in LB media. Cells from the 
starter culture were pellet down and resuspended in minimal media supplemented 
with 2 mM MgSO4, 0.1 mM CaCl2 and 0.4 % glucose as the carbon source. Cells 
were grown until the OD600=0.5 and methionine biosynthetic pathway was inhibited 
by adding 1 mg Lysine, 1 mg threonine, 1 mg phenylalanine, 0.5 mg leucine, 0.5 mg 
isoleucine, 0.5 mg valine, and 0.5 mg L-selenomethionine per liter media. 
Temperature was lowered to 220 C, 200 rpm and cells were induced with 50 µM 
IPTG 30 minutes after adding the amino acids mixture. Cells were induced for 20 
hours. 
2. MmP5CDH   
a. cloning 
MmP5CDH gene (NP_780647.3) was obtained from ATCC. To delete the 
mitochondrial leader sequence, the gene was amplified from residues 21-562 using 
primers AACCAATGCCATATGCTGCGATGGAAGCACACCTC and 
AACTGCAGACTCGAGTCACTGCATGTAGGAGTATCGC as sense and 
antisense primer respectively. The gene was cloned between the NdeI and XhoI 
restriction sites of pET28a vector. 
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b. expression and purification 
MmP5CDH-pET28a was transformed in to Bl21(DE3)pLysS competent cells. Two 
liters of LB media, supplemented with 50 µg/ml kanamycine, were inoculated with 1 
% overnight grown starter culture. Cells were grown at 370 C/ 250 rpm until an 
OD600 of 0.6 then induced with 0.5 mM IPTG for overnight at 220 C/200 rpm.  
Cells were harvested by centrifugation at 3500 rpm for 30 min. and resuspended in 
to 20 mM Hepes, 60 mM NaCl, 5 % glycerol, pH 8.0. Cells were quick frozen into 
liquid nitrogen and stored at -800 C until further purification.   
The stored cells were thawed and broken by sonication and cell debris was cleared 
by centrifugation at 16500 rpm for 1 hour. The recovered supernatant was applied to 
a HisTrap HP Ni-affinity column pre-equilibrated with buffer A ( 20 mM Hepes, 300 
mM NaCl, 5 % glycerol, pH 8.0). The column was washed with buffer A and buffer 
A plus 30 mM Imidazole. Protein was eluted with buffer A plus 300 mM Imidazole. 
The column was washed with  buffer B (20 mM Hepes, 300 mM NaCl, 1 M 
Imidazole, 5 % glycerol, pH 8.0) for next round of purification. 
Mouse P5CDH, purified from Ni affinity column, was dialyzed into 50 mM Tris, 0.5 
mM EDTA, 0.5 mM THP, 5 % glycerol, pH 7.5 and loaded onto HiTrap Q anion 
exchange column. Protein was eluted with continuous gradient of NaCl from 0 to 1 
M. 
Fractions were analyzed by SDS-PAGE, pooled and dialyzed in to pre-
crystallization buffer (50 mM Tris, 50 mM NaCl, 0.5 mM EDTA, 0.5 mM THP, 5 % 
glycerol, pH 7.5)   
3. Put2 
a. Cloning 
The Put2 gene, cloned between the NdeI and BamHI restriction sites of the pKA8H 
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vector, was obtained from the Donald Becker lab. To delete the leader sequence, the 
gene was amplified from residues 23-575 using 
AAACATATGAAGCCCCCCAAGCACATAAG as the forward primer and T7 
terminator as the reverse primer. The Put2 gene without leader sequence was cloned 
into the pKA8H vector between the NdeI and BamHI restriction sites. 
b. Expression and purification 
Put2-pKA8H was transformed into Bl21(DE3)pLysS competent cells. One liters of 
LB media, supplemented with 100 µg/ml ampicillin, was inoculated with 1 % 
overnight grown starter culture. Cells were grown until the OD600 = 0.6 at 370 C/250 
RPM and induced with 0.5 mM IPTG for 8 hours at 220 C/200 rpm.  
Cells were harvested by centrifugation at 3500 rpm for 30 minutes and resuspended 
in to 20 mM Hepes, 60 mM NaCl, 5 % glycerol, pH 8.0. Cells were quick frozen 
into liquid nitrogen and stored at -800 C until further purification.   
The cells were broken by sonication and cell debris was cleared by centrifugation at 
16500 rpm for one hour. The supernatant was applied to HisTrap HP Ni affinity 
column, pre-equilibrated with buffer A ( 20 mM Hepes, 300 mM NaCl, 5 % 
glycerol, pH 8.0). The column was washed with buffer A and buffer A plus 30 mM 
Imidazole. Protein was eluted with buffer A plus 300 mM Imidazole. The column 
was washed with buffer B (20 mM Hepes, 300 mM NaCl, 1 M Imidazole, 5 % 
glycerol, pH 8.0) for next round of purification. 
Put2 purified from the Ni-affinity column was dialyzed into 50 mM Tris, 0.5 mM 
EDTA, 0.5 mM THP, 5 % glycerol, pH 8.0 and loaded onto a HiTrapQ anion 
exchange column. Protein was eluted with continuous gradient of NaCl from 0 to 1 
M. 
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Fractions were analyzed by SDS-PAGE, pooled and dialyzed in to pre-
crystallization buffer (50 mM Tris, 150 mM NaCl, 0.5 mM EDTA, 0.5 mM THP, 5 
% glycerol, pH 8.0)   
B. Crystallization 
1. HsP5CDH 
a. Crystal screening 
Initial crystallization conditions were identified using crystal-screening kits. Screens 
were performed using both the His-tagged enzyme and the tag-free enzyme at 40 C 
and at room temperature respectively. The sitting drop method of vapor diffusion 
was used with drops formed by mixing 1 µL of the enzyme and 1 µL of the reservoir 
solution.  These experiments led to two crystal forms having hexagonal (40 C, His-
tagged) and primitive monoclinic lattices (200 C, Untagged).  
(1) Hexagonal crystal form – 
Hexagonal crystal form were grown in 20-25 % PEG3350, 0.2 M (NH4)2SO4, 0.1 M 
HEPES, pH 7.0-8.0 at 40 C. Crystals were cryoprotected with 25 % PEG3350, 0.2 M 
(NH4)2SO4, 0.1 M HEPES, 25 % glycerol, pH 7.5 and quick frozen by plunging the 
looped crystals in to liquid nitrogen. 
(2) Monoclinic crystal form –  
Monoclinic crystal form were grown in 20-25 % PEG3350, 0.2 M MgCl2, 0.1 M 
HEPES, pH 7.0-8.0 at 200 C. Crystals were cryoprotected with 25 % PEG3350, 0.2 
M MgCl2, 0.1 M HEPES, 20 % PEG200, pH 7.5 and quick frozen by plunging the 
looped crystals in to liquid nitrogen. 
(3) Crystallization of Se-Met darivative 
The Se-Met darivative of human P5C dehydrogenase was crystallized in the 
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hexagonal crystal form. The crystals were grown in 20-25 % PEG3350, 0.2 M 
(NH4)2SO4, 0.1 M HEPES, pH 7.0-8.0 at 40 C. Crystals were cryoprotected with 25 
% PEG3350, 0.2 M (NH4)2SO4, 0.1 M HEPES, 25 % glycerol, pH 7.5 and quick 
frozen by plunging the looped crystals in to liquid nitrogen. 
(4) Crystallization of HsP5CDH S352L 
        S352L failed to crystallize in the forms that had been obtained for the native 
enzyme.  However, crystal screening trials revealed a triclinic form that grew in 20-
25 % PEG3350, 0.1 M HEPES, 0.2 M MgCl2, pH 7.0-8.0 using untagged HsP5CDH 
S352L at 3.5 mg/ml.   
 
2. MmP5CDH 
Mouse P5CDH crystals was grown in 20-25 % PEG3350, 0.2 M Li2SO4, 0.1 M Bis-
Tris, pH 6.0-7.0. One ml of protein was mixed with equal volume of reservoir 
solution in a sitting drop crystal tray and incubated at 20° C. Crystal typically 
appears within 24 hours.  
MmP5CDH crystals were cryoprotatected with 25 % PEG3350, 0.2 M Li2SO4, 0.1 
M Bis-Tris, 25 % glycerol, pH 6.25. For getting the ligand bound structure, crystals 
were soaked with a saturating concentration of glutamate in cryosolution (300 mM), 
20 mM NAD+, 20 mM NADH, 20 mM NADH + 300 mM glutamate, and 150 mM 
proline for 6-8 hours.    
3. Put2 
Put2 crystals were grown in 8-14 % PEG3350, 0.1 M (NH4)2SO4, 0.1 M Bis-Tris, 
pH 5.5-6.5. One µl of protein was mixed with equal volume of reservoir solution in 
sitting drop crystal tray and incubated at 200 C. crystals were cryoprotected with 15 
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% PEG3350, 0.1 M (NH4)2SO4, 0.1 M Bis-Tris, pH 6.0, 20 % glycerol.  
C. X-ray data collection 
1. Se-Met hexagonal 
Hexagonal crystals of Se-Met HsP5CDH were analyzed at the NE-CAT beamline 
24-ID-C at the Advanced Photon Source using a Quantum 315 detector.  The data 
set that was used for single-wavelength anomalous diffraction (SAD) phasing was 
collected at the energy corresponding to the experimentally determined peak of f’’ 
(wavelength = 0.979181 Å). This data set consisted of 180 frames collected with an 
oscillation width of 1.0° per image, detector distance of 375 mm, exposure time of 
1.0 s/image, and transmission of 2.5 %.  The data were processed to 2.85 Å 
resolution using HKL200011, with I+ and I- treated as nonequivalent reflections 
during scaling.  The crystal was then translated, and a second data set was collected 
at higher transmission for purpose of phase extension and refinement.  Denoted as 
Se-Met-2 in Table 4.2, this data set consisted of 60 frames collected with an 
oscillation width of 1.0° per image, detector distance of 350 mm, exposure time of 
1.0 s/image, and transmission of 10.0 %.  The data were processed using HKL2000 
to 2.5 Å resolution, with I+ and I- treated as equivalent reflections during scaling. 
2. Native data set – Primitive monoclinic crystals of HsP5CDH were also analyzed 
at NE-CAT beamline 24-ID-C (Table 4.2).   The data set used for refinement 
consisted of 180 frames collected with an oscillation width of 1° per image and 
detector distance of 250 mm. The data were processed to 1.95 Å resolution with 
HKL200011. 
3. Human P5C dehydrogenase S352L mutant – Triclinic crystals of S352L 
were analyzed at NE-CAT beamline 24-ID-E (Table 4.2).  Reflections collected 
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from two crystals were merged to obtain a data set with acceptable completeness and 
redundancy.  One of the data sets consisted of 163° of reflections collected with an 
oscillation width of 1° and detector distance of 325 mm.  The other set consisted of 
180° of data (1° oscillation width and detector distance of 330 mm).  The data sets 
were integrated separately with MOSFLM12 through the iMosflm graphical 
interface.  The integrated reflections were combined with Pointless and scaled to 
2.55 Å resolution with SCALA13 using the CCP4i interface14. 
 
d. MmP5CDH native crystals – Data sets from MmP5CDH crystals were 
collected at NE-CAT beamline 24-ID-C and beamline 4.2.2 of the Advanced Light 
Source (Table 4.3).  For the enzyme-sulfate complex, a 120° data set was collected 
with an oscillation width of 1° and detector distance of 150 mm.  The data were 
processed with HKL200011. Data sets for the other complexes were collected at 4.2.2 
and consisted of 180° scans with an oscillation width of 0.5° and detector distance of 
100 mm.  These data sets were integrated with XDS15 and scaled with SCALA. 
e. Put2 native – Put2 crystals were analyzed at the NE-CAT beamline 24-ID-
C at the Advanced Photon Source using a Quantum 315 detector.  
D. Phasing and refinement 
1. HsP5CDH 
a. Se-Met phasing – Molecular replacement calculations using search models 
derived from the TtP5CDH structure were unsuccessful, therefore the structure of 
HsP5CDH was solved using SAD phasing based on data collected hexagonal crystals of 
Se-Met HsP5CDH.   The phasing potential of each data set was analyzed with the 
HKL2MAP16 interface to the SHELXC/D/E programs17,18.  Promising data sets were 
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input to PHENIX AutoSol for SAD phasing, density modification, and automated 
building calculation19.  Thirty of the expected 36 selenium sites (i.e., four HsP5CDH 
molecule per asymmetric unit) were identified, which resulted in a figure of merit of 0.39 
for reflections to 2.85 Å resolution.  Density modification, which included 4-fold 
noncrystallographic symmetry averaging, increased the figure of merit to 0.69.  The 
model from automated building included 1790 residues (10194 atoms) and had an R-
factor of 0.48 and map-model correlation coefficient of 0.59.  PHENIX AutoBuild19 was 
used for phase extension to 2.5 Å resolution and additional model building.  The resulting 
model included 1751 protein residues and 505 water molecules, and had an R-factor of 
0.32, R-free of 0.37, and map-model correlation coefficient of 0.72.   
The model from automated building was used as the starting point for several rounds of 
manual building in COOT20 and simulated annealing refinement against the 2.5 Å 
resolution hexagonal data set in PHENIX19. The B-factor model used during refinement 
consisted of an isotropic B-factor for each non-hydrogen atom plus one TLS group per 
chain.  
b. P21 molecular replacement – The structure of monoclinic HsP5CDH was 
solved using molecular replacement phasing as implemented in the programs MOLREP21 
and PHASER22,23.  The structure could be readily solved with either program using 
monomer or dimer search models.  A clear solution having two dimers in the asymmetric 
unit was obtained in space group P21.  The model from molecular replacement was 
improved through rounds of manual building in COOT20 and simulated annealing 
refinement to 1.95-Å resolution in PHENIX19.  Refinement statistics are provided in 
Table 4.3. 
c. Human P5C dehydrogenase S352L mutant – Structure of the S352L 
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mutant of human P5C dehydrogenase was solved by molecular replacement phasing as 
described for the human P5C dehydrogenase monoclinic crystal form. The structure was 
solved in space group P1 using dimer as the search model. I am using strict NCS 
refinement as implemented in CNS24 and manual building in Coot20 to improve the model 
from molecular replacement.    
2. Mouse P5C dehydrogenase molecular replacement – Structure of the 
mouse P5C dehydrogenase was solved by molecular replacement phasing as described 
for the monoclinic crystal form of human P5C dehydrogenase. Human P5C 
dehydrogenase dimer was used as the search model. A clear solution with one dimer in 
the asymmetric unit was obtained in space group P12121. The model from molecular 
replacement was improved through rounds of manual building in COOT and simulated 
annealing refinement to 1.30-Å resolution in PHENIX. The coordinates of the protein 
part of the 1.3 Å resolution MmP5CDH structure served as the starting point for 
refinements of  MmP5CDH complexes.Refinement statistics are provided in Table 4.3.   
3. Put2 molecular replacement – Structure of Put2 was solved by molecular 
replacement phasing. Mouse P5C dehydrogenase dimer was used as the search model and 
structure was solved in P65 space group with one dimer in the asymmetric unit. I am 
using manual building in Coot and simulated annealing refinement in PHENIX to 
improve the model obtained from molecular replacement.  
E. Kinetics 
1. Standard bi-substrate kinetics 
Kinetics of human P5CDH and its five mutants, S352L, S352A, F388L, V470I and 
T473A were done in 100 mM PO–4, 1 mM EDTA, pH 7.0. Kinetics of wild type and 
mutants, except S352L, were done at different concentration of NAD+ and P5C using 10 
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µg / ml enzyme. Kinetics of S352L was done using 200 µg / ml enzyme, 0.2 mM P5C, 
and 0.35 mM NAD+. Formation of NADH was followed by increase in absorption at 340 
nm.  
To determine the kinetic parameters, data was globally fitted to following equation.  
 
 
         
              Equation (1) 
      
2. P5C vs. OH-P5C kinetics 
To determine the relative activity of human P5C dehydrogenase for the oxidation of P5C 
and OH-P5C, P5C and OH-P5C were generated in situ using 30 and 70 µg/ml PutA86-
630 Y540S enzyme for proline and hydroxy-proline respectively and varying amounts of 
proline or hydroxy-proline in 20 mM HEPES, 10 mM MgCl2, pH 8.0. 70 µg/ml 
HsP5CDH was used for the assay. Formation of glutamate, or hydroxy-glutamate, was 
followed by fluorescence of NADH with λex=340 nm and λem=460 nm. Rate of P5C or 
OH-P5C production at different proline/hydroxy-proline concentration by PutA86-630 
Y540S was measured using o-Aminobenzaldehyde and following the increase in 
absorption at 443 nm.   
F. Equilibrium analytical ultracentrifugation – The quaternary structures 
of Human and mouse P5C dehydrogenase and Put2 in solution were analyzed using 
equilibrium analytical ultracentrifugation25.  Data were acquired at 20 °C using a 
Beckman XL-I Optima analytical ultracentrifuge equipped with an An50Ti rotor.  
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Prior to centrifugation, a protein sample having concentration of 0.8 mg/mL was 
dialyzed into a buffer containing 50 mM Tris, 50 mM NaCl, 0.5 mM EDTA, 0.5 mM 
THP, 5 % glycerol, pH 8.0 for human P5C dehydrogenase and pH 7.5 for mouse P5C 
dehydrogenase and Put2.  Absorbance data (278 nm) were collected at three protein 
concentrations (0.2 mg/mL, 0.4 mg/mL, 0.8 mg/mL) and three rotor speeds (4000 rpm, 
8000 rpm, 12000 rpm for human P5C dehydrogenase and 5000, 7500 and 10000 for 
mouse P5C dehydrogenase and Put2).  
The nine sets of data were fit globally to a single-species model (equation 2) using 
Origin 8.  
 
€ 
c(r) = c(ro)exp
Mω 2(1−ν ρ)
2RT r
2 − ro2( )
⎡ 
⎣ 
⎢ 
⎤ 
⎦ 
⎥ + BL                Equation (2) 
 
In this equation, cI is the total protein concentration at radial position r; c(ro) is the 
protein concentration at an arbitrary reference position, ro; M is the molecular weight; ω 
is the radial velocity (rad/s); ν is the partial specific volume of the protein; ρ is the 
solvent density; R is the gas constant; T is the absolute temperature; and BL is a baseline 
offset.  A solvent density of 1.02 g/cm3 was employed for the calculations, and the partial 
specific volume was assumed to be the value predicted from the amino acid sequence 
0.74 cm3/g. 
G – Isothermal titration calorimetry – Wild type human P5C dehydrogenase, 
S352A and S352L mutants were dialyzed in 50 mM Tris, 50 mM NaCl, 0.5 mM THP, 
0.5 mM EDTA, 5 % glycerol, pH 8.0 with three exchanges of buffer. The protein 
concentration was measured by using extinction coefficient of 1.1 / mg P5C 
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dehydrogenase at 280 nm. pH of the protein was measured, NAD+ was dissolved in 
dialysis bath and its pH was adjusted to that of protein solution. Concentration of NAD+ 
was measured by absorbance at 259 nm with an extinction coefficient of 16.9 / mM. 
About 1.8 mL of protein solution, at 1 mg /ml (17.6 µM) was loaded in to ITC reaction 
cell and titrated with 200 µM of NAD+ solution. First injection volume was 4 µl and the 
rest of the injection volume was 20 µl, which was injected into the ITC reaction cell at 
the interval of 240 seconds. The experiments were done at 25o C with stirring speed of 
250 rpm. The data was analyzed by Origin software.    
 
Results	  –	  	  
Structure of human P5C dehydrogenase was determined at 2.5-Å resolution by 
Se-Met phasing using hexagonal crystal form. There are four protein chains and two 
biologically active dimers in the asymmetric unit. P5C dehydrogenase belongs to ALDH 
superfamily and its structure and overall fold is similar to other ALDH superfamily 
members. It has a NAD+ binding domain, a catalytic domain (residue 316-514) and a 
dimerization domain (residue 183-199, 542-550), which interacts with the catalytic 
domain of the other subunit to form a dimer (Fig. 4.1, 4.2). NAD+ binding domain has 
distorted Rossmann dinucleotide binding fold, which was first discovered in aldehyde 
dehydrogenase 3 (ALDH3) and is found in aldehyde dehydrogenase superfamily. It has 
five parallel and two antiparallel β-strand connected by four helix. Catalytic domain have 
seven parallel and two antiparallel β-strands, two of them being contributed from the 
dimerization domain of other subunit. Catalysis occurs between the cleft formed by the 
NAD+ binding and the catalytic domain. The two subunits of biologically active dimer 
are similar to each other with root mean square deviation of 0.18 Å except the very end of 
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the N-terminus. In this study, it was noticed that the dimerization domain is also involved 
in higher order oligomer formation by aldehyde dehydrogenases. Since this crystal form 
was grown in 20-25 % PEG3350, 0.1 M HEPES (pH 7.0-8.0), and 0.2 M (NH4)2SO4, 
there was a  
sulphate ion bound to the active site. As a result, this structure is a mimic of substrate 
bound state. 
A higher resolution structure of human P5C dehydrogenase in monoclinic crystal 
form was solved by using search model obtained from hexagonal crystal form. This 
crystal was grown in 20-25 % PEG3350, 0.1 M HEPES (pH 7.0-8.0), and 0.2 M MgCl2. 
This structure represents the ligand free state of the protein. There are four protein chains 
and two biologically active dimers in the asymmetric unit.  
Structure of mouse P5C dehydrogenase was solved at 1.3 Å resolution by 
molecular replacement using human P5CDH as the search model. There are two protein 
chains in the asymmetric unit making the biologically active dimer. The mouse P5CDH 
structure is very similar to human P5CDH structure with root mean square deviation of 
0.22 Å for one chain and 0.24 Å for both chain (Fig. 4.3). Structure of yeast Put2 was 
solved by molecular replacement using mouse P5CDH as search model. Although the 
overall fold of yeast Put2 is very similar to human P5C dehydrogenase, but the root mean 
square deviation between one chain of human P5C dehydrogenase and Put2 is 1.11 Å and 
both chain is 1.69 Å. Visual analysis of the alignment between human or mouse P5C 
dehydrogenase (dimeric) and Put2 or Thermus thermophilus P5C dehydrogenase 
(hexameric) suggests that the relative orientation of one subunit relative to the other is 
different in dimeric and hexameric P5C dehydrogenase (Fig. 4.4) 
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The dimerization domain and the dimer interface – Two P5CDH 
subunit makes a domain swapped dimer by intermolecular β-sheet formation involving β-
sheet of the catalytic domain and two β-strand of the dimerization domain from the other 
subunit (Fig. 4.2). Some aldehyde dehydrogenases have three β-strand from the 
dimerization domain involved in intermolecular β-sheet formation. Apart from the 
dimeric interface discussed above, an additional intermolecular interaction has been 
observed involving a helix (residue 288-305). This helix interacts with the same helix 
from the other subunit. This helix along with helix 266-281 sandwich the adenine group 
of NAD+ and has been suggested to be involved in intersubunit communication in 
ALDH2. Human and mouse P5CDH have relatively long C-terminus which is also 
involved in intersubunit interaction. The interface area, calculated with EBI-PISA, is 
9246 Å2 with 77 hydrogen bonding and 31 salt bridge interaction. It has 928 atoms and 
252 residues (Fig. 4.5).  
Active site and conformational changes associated with ligand 
binding – Human P5CDH in hexagonal crystal form and mouse P5CDH was grown in 
a condition that has 0.2 M SO4--, consequently sulphate ion was bound in the active site 
and occupies the same site as the main chain carboxylic group of glutamate or γ-glutamyl 
semialdehyde (Fig. 4.6). Since mouse P5C dehydrogenase structure is very similar to its 
human homologue, mouse P5C dehydrogenase crystals were used for soaking 
experiments. Structure of mouse P5C dehydrogenase with bound glutamate was obtained 
by soaking the crystal with a saturated solution of glutamate (~300 mM) in cryo-solution   
(25 % PEG3350, 25 % glycerol, 0.2 M Li2SO4, 0.1 M Bis-Tris, pH 6.25) (Fig. 4.7). α-
carboxylic group of glutamate makes hydrogen bonds with backbone amide group of 
Gly512 and Ser513 and hydroxyl group of Ser349 and Ser513. Amine group of glutamate 
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also makes hydrogen-bonding interaction with hydroxyl group of Ser513. Besides direct 
interaction of glutamate with protein atoms, there are three water mediated hydrogen-
bonding interaction between protein atoms and glutamate. These are interactions between 
carboxyl group of glutamate and amine group of Lys347 and interaction between amine 
group of glutamate with hydroxyl and carbonyl group of Ser513 and carboxylic group of 
Glu165. Sulphate ion, which is present in the active site of human P5CDH hexagonal 
crystal form and mouse P5CDH structure, make the same interaction with the protein that 
carboxylic group of glutamate make i.e. interaction with the backbone N-H group 
of Gly512 and Ser513 and hydroxyl group of Ser513 and Ser349. The side chain 
carboxylic group of glutamate, which is a mimic of aldehyde group of γ-glutamyl 
semialdehyde, interacts with backbone N-H group of Cys348 and Asn211 side chain.  
Structure of human P5CDH in monoclinic crystal form do not have sulphate ion 
bound to the active site. There are some regions of protein, disordered in this structure. 
There are four molecules in the asymmetric unit. Residues 514-535 are disordered in one 
subunit of each dimer. Part of this region except residue 515-521, is ordered in the other 
subunit. However, the conformation of this region is different from mouse P5CDH, 
human P5CDH in hexagonal form and Thermus thermophilus P5CDH (Fig. 4.8). 
Residue 183-193 is disordered in one subunit of each dimer while only residue 
188-193 is disordered in the other subunit. Conformation of residue 183-188 is different 
from the mouse P5CDH structure. The C-terminus end of the human P5CDH is also 
disordered in all the four chain.  
Cofactor binding – NAD+ and NADH complex of mouse P5CDH were 
obtained by soaking the crystals with 20 mM NAD+ or NADH. NAD+ and NADH bind to 
the P5C dehydrogenase in extended conformation with adenine ring sandwiched between 
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the two helices, helix 288-304 and helix 266-275. The ribose group adjacent to adenine 
ring interacts, through its hydroxyl group, with side chain amine group of Lys233 and 
backbone carbonyl group of Ser208 (Fig. 4.9). 
However the conformation of pyrophosphate group, ribose group adjacent to 
nicotinamide, and nicotinamide ring are different in NAD+ and NADH complex. Because 
of the movement of pyrophosphate group, Nicotinamide ribose group is pulled away 
from the active site in NADH complex (Fig.4.10). Hydroxyl group of Nicotinic ribose 
group interacts with a conserved glutamate (Glu447) and Arg399 residue. 
Cys315 and Gly316 have two conformations. In one conformation, Cys315 
carbonyl group point towards NAD+ amide group while in the other conformation it 
points away from NAD+ amide group. Glu314 is disordered in all the structure of 
MmP5CDH.  
 Conformation of the loop (208-217) adjacent to the ADP-ribose group is different 
in monoclinic crystal form of human P5CDH and in mouse P5CDH. Conformation of this 
loop in monoclinic crystal form is such that NAD+ binding will create a steric clash 
between ADP-ribose group and Ser208 and Pro209.  
Single nucleotide polymorphism – There are six single nucleotide 
polymorphism reported to be present in human P5C dehydrogenase. These are E277K, 
S352L, G366R, F388L, V470I and T473A. S352L is known to be responsible for the type 
II hyperprolinemia. The role of the other mutations in disease is not known. Effect of 
these mutations on the enzymatic activity of human P5CDH is unknown. Residue Glu277 
and Gly366 are on the surface of the protein. However Ser352, Phe388, Val470, and 
Thr473 are buried inside the protein structure (Fig. 4.11). Ser352 is close to the active site 
and near the catalytic cysteine (Cys348). This residue is surrounded by polar residues and 
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is connected to the catalytic loop and backbone atom of catalytic cysteine through a 
hydrogen-bonding network. This hydrogen-bonding network connecting the Ser352 and 
catalytic cysteine is shown in Fig. 4.12 using mouse P5CDH as a higher resolution model 
of human P5C dehydrogenase. In addition, Fig. 4.12 Also shows that residue Ser349 is 
involved in substrate recognition and interacts with the carboxylic group of glutamyl 
semialdehyde thus helping to position the aldehyde group near catalytic cysteine.  
Structure of human P5C dehydrogenase S352L mutant – Structure 
of S352L mutant of human P5C dehydrogenase was solved in monoclinic crystal form at 
2.6 Å resolution. There are eight molecules in the asymmetric unit making four dimer. 
Overall fold of the mutant enzyme and the structure of dimer are similar to wild type 
enzyme except the conformation of catalytic loop. There are significant conformational 
changes in residues 348-352, which shows shift towards NAD+ binding loop (residues 
445-452) (Fig. 4.13). Structural alignment between mouse P5C dehydrogenase-NAD+ 
complex and human P5C dehydrogenase S352L mutant shows that Ser349 residue of 
S352L mutant occupies the place occupied by Glu447 (Fig. 4.14). 
Kinetic characterization of human P5C dehydrogenase – Steady 
state kinetics of human P5C dehydrogenase and its mutants were done with NAD+ as 
changing fixed substrate and P5C as variable substrate. At one fixed concentration of 
NAD+, P5C was varied from 22 µM to 600 µM and the same experiment was repeated at 
different concentration of NAD+. Kinetic parameters were obtained by globally fitting the 
data to following equation for compulsory ordered bi-bi reaction. 
 
                        Equation (1)
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€ 
KiNAD  is the dissociation constant of P5CDH-NAD+ complex,  is the 
concentration of NAD+ at saturating concentration of P5C which yield a velocity of  
½ Vmax and  is the concentration of P5C at saturating concentration of NAD+ 
which yield a velocity of ½  Vmax. Human P5C dehydrogenase showed the 
phenomenon of substrate inhibition by P5C at high P5C concentration (~600 µM), 
which is more pronounced at lower NAD+ concentration. So the data point showing 
the substrate inhibition was discarded from the analysis.  
   
€ 
KiNAD     
€ 
KiNAD  The graphs of P5C concentration vs. rate of NADH 
production and global fit analysis of wild type enzyme and different mutants are 
shown in Figure 4.15 to 4.17. The kinetics parameters are shown in Table 4.4.    
   
€ 
KiNAD     
€ 
KiNAD  Both the mutants have similar kinetic parameters as 
wild type enzyme except S352L mutant. S352L mutant of human P5C dehydrogenase is 
150 fold less active then wild type under similar reaction condition even when S352L 
mutant was used in 20 fold excess. However, S352A mutant has comparable activity as 
wild type enzyme (Table 4.4). 
Thermodynamics of NAD+ binding to wild type human P5C 
dehydrogenase, S352A and S352L mutants – Thermodynamic parameters for 
NAD+ binding to wild type human P5C dehydrogenase and two mutants, S352A and 
S352L were measured by using isothermal titration calorimetry (ITC). Data was fitted to 
single site model. NAD+ binding to wild type human P5C dehydrogenase is highly 
exothermic with enthalpy of NAD+ binding -16980 ± 2195 Kcal/mole, dissociation 
constant of 6.6±1 µM and entropy of -33.27 Kcal/mole. The stoichiometry of NAD+ 
binding is 0.57±0.06 suggesting half-the-sites reactivity for P5C dehydrogenase where 
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only one subunit of the dimer binds to the NAD+. The ITC experiment for S352A was 
repeated four times and data were fitted globally for four parameters; association 
constant, stoichiometry, enthalpy, and base line. Dissociation constant, enthalpy and 
entropy of NAD+ binding to S352A mutant are 10.37±2.42 µM, -20539±4731 Kcal/mole 
and -47.89 Kcal/mole. NAD+ binding to S352A has similar stoichiometry to wild type 
enzyme, 0.47±0.05. However there was no detectable NAD+ binding to S352L when 
isothermal titration calorimetry (ITC) was done under the similar experimental condition.  
Oxidation of 3-OH-P5C by P5C dehydrogenase – It has been suggested, 
based on genetic evidence, that P5C dehydrogenase also catalyzes the oxidation of 3-OH-
P5C to hydroxy-glutamate, a degradation product of hydroxy-proline catabolism26.  
 
Ostrander et al.27 have prepared a mutant of E. coli PutA 86-630 Y540S, which 
can also oxidize OH-Proline to OH-P5C, although seven times less efficiently then 
proline. PutA86-630 Y540S mutant was used to generate P5C and 3-OH-P5C in-situ 
using varying amount of proline and OH-Proline. P5C dehydrogenase present in the 
reaction mixture, oxidizes the P5C/OH-P5C thus produced, to glutamate/hydroxy-
glutamate with the concomitant reduction of NAD+ to NADH. The reaction is described 
in the figure below.   
The oxidation of P5C/3-OH-P5C to glutamate can be followed by increase in 
absorbance at 340 nm due to formation of NADH. However coenzyme Q1 (Ubiquinone 
1, UQ1) was used to reoxidize the FAD cofactor of PutA86-630 Y540S for further round 
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of catalytic cycle. Coenzyme Q1 shows a decrease in absorption at 340 nm after 
reduction. To overcome the problem of spectral overlap, NADH fluorescence was used to 
follow the oxidation of P5C/OH-P5C. Fluorescence of NADH was converted to the 
NADH concentration by making a NADH standard curve (Fig. 4.25). Fig. 4.24 shows the 
formation of NADH at three different concentration of proline/OH-proline. This figure 
also shows that there is no NADH formed, when P5C dehydrogenase was absent from the 
reaction mix. Since PutA86-630 Y540S catalyze the oxidation of hydroxy-proline less 
efficiently than proline, a higher amount of this enzyme was used for hydroxy-proline. 
Rate of P5C/OH-P5C production was measured using o-aminobenzaldehyde. ο-
aminobenzaldehyde react with γ-glutamyl semialdehyde to make an adduct which 
absorbs at 443 nm with extinction coefficient of 2.71. Figure 4-29 shows the rate of 
production of NADH at 150, 300, and 450 mM proline and hydroxy-proline. There is 
decrease in rate of NADH production with increasing concentration of proline. However 
rate of production of P5C at 150, 300 and 450 mM proline was 11.5, 11.3 and 11.45 
µM/min. For hydroxy-proline, rate of production of NADH are similar at all the three 
concentration of hydroxy-proline. However the rate of production of 3-OH-P5C at 150, 
300 and, 450 µM hydroxy-proline was 10.66, 15.79 and 19.5 µM/min.     
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Quaternary structure of P5C dehydrogenase – Quaternary structure of P5C 
dehydrogenase in solution was studied by using equilibrium analytical 
ultracentrifugation. Molecular weights of monomer of human and mouse P5C 
dehydrogenase (His-tagged) and Put2 (untagged) are 62.07, 61.87, and 62.61 Kda, as 
calculated from sequence using ProtParam (http://expasy.org/cgi-bin/protparam).  Data 
from equilibrium analytical ultracentrifugation was fitted to one species model by 
simultaneously fitting nine data from three different protein concentrations and three 
different rotor speeds. The fitted data for human P5C dehydrogenase, mouse P5C 
dehydrogenase and Put2 are shown in figure 4.26, 4.27 and 4.28 respectively. Molecular 
weights of human and mouse P5C dehydrogenase were 118 ± 1 Kda and 134±1 Kda 
respectively. Molecular weight of Put2 was 313± Kda.  
 
Discussion:	  
In the present study, we have solved the crystal structure of eukaryotic P5C 
dehydrogenase representing first of its kind. P5C dehydrogenase from three different 
organisms (human, mouse and yeast) was solved using four different crystal forms. These 
structures shed light on the substrate recognition and associated conformational changes, 
molecular mechanism of type II hyperprolinemia and structural basis of different 
oligomeric state in P5C dehydrogenase and aldehyde dehydrogenase. 
   Crystallization conditions of human P5C dehydrogenase (hexagonal crystal 
form), mouse P5C dehydrogenase and Put2 had sulphate ion. There was a sulphate ion, 
bound to the active site of these structures. The sulphate ion occupies the same place as 
occupied by a-carboxylic group of glutamate (or γ-glutamyl semialdehyde). This sulphate 
ion connects Ser349 with Gly512 and Ser513 through hydrogen bonding interactions, 
therefore restricting the conformational flexibility of residues 514-535. Structure of 
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human P5C dehydrogenase in monoclinic crystal form was crystallized in a condition 
without sulphate ion. Consequently there is no sulphate ion bound to the active site of this 
structure and residues 514-535 is disordered or only partially ordered. The corresponding 
residues are also disordered in retinal dehydrogenase and binding of retinal to retinal 
dehydrogenase restrain its flexibility and order it28. We suggest that in the absence of 
substrate, residues 514-535 are disordered in human P5C dehydrogenases and substrate 
binding induces a conformational change inducing the ordering of residues 514-535. This 
ligand induced conformational changes also explain why succinic semialdehyde, which is 
one carbon shorter than γ-glutamyl semialdehyde, is a poor substrate in comparison to g-
glutamyl semialdehyde.  
Structure of mouse P5C dehydrogenase was also solved in NAD+ and NADH 
bound state. In the structure of mouse P5C dehydrogenase complex, nicotinamide ring of 
NAD+ is in the active site. Consequently, to prevent the steric clash with nicotinamide 
group, the sulfhydryl group of catalytic cysteine (Cys348) is pointing towards the active 
site. However, in the structure of P5C dehydrogenase-NADH complex, nicotinamide ring 
of NADH is pulled back from the active site. Glu314 is disordered in all the structure of 
mouse P5C dehydrogenase.  However the corresponding residue in Thermus 
thermophilus P5C dehydrogenase9 and other aldehyde dehydrogenases show two 
conformations; in NAD+ bound state, Glu314 side chain points away from the active site 
and in NAD+ free state, it points towards the active site. This residue serves as a general 
base during catalysis. During catalysis in aldehyde dehydrogenase, thiolate ion formed by 
deprotonation of catalytic cysteine attacks the carbonyl carbon of the aldehyde group of 
the substrate making a thiohemiacetal intermediate29. The second step is hydride transfer 
from the thiohemiacetal intermediate to NAD+ making thioester intermediate and NADH. 
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The last step is the hydrolysis of thioester intermediate to yield free cysteine and 
carboxylic acid. It requires activation of water molecule by Glu314, which must be 
pointing towards the active site. All the aldehyde dehydrogenases show the NADH 
isomerization where Nicotinamide ring (as well as nicotinic ribityl and pyrophosphate 
group) either completely dissociated from the enzyme while adenosine moiety still 
attached to the enzyme or Nicotinamide ring is pulled back from the active site due to 
conformational changes in the nicotinic ribityl and pyrophosphate group30. The 
isomerization of NADH allows Glu314 to swing back towards the active site and activate 
the water molecule, which attacks on the thioester intermediate to release carboxylic acid. 
S352L mutation in human P5C dehydrogenase gene causes type II 
hyperprolinemia. Structure of S352L mutant along with kinetics and thermodynamics 
was used to understand the molecular mechanism of type II hyperprolinemia caused by 
S352L mutation. The structure suggests that there is a significant conformational change 
in the catalytic loop (residues 348-352). This conformational change in catalytic loop put 
Ser349 in a place previously occupied by carboxylic group of Glu447, causing 
displacement of Glu447 due to steric clash. Glu447 is conserved among aldehyde 
dehydrogenase and interacts with the nicotinic ribose group of NAD+. Mutation or any 
change in the conformation of this residue may affect NAD+ binding. Further, S349 
interacts with the side chain carboxylic group of substrate and position the substrate in 
catalytically competent conformation. Due to the conformational changes in the catalytic 
loop, S349 will no longer be able to serve its purpose and S352L mutant will not be able 
to binds to the substrate. Most importantly, there is significant displacement of catalytic 
cysteine residue (Cys348) in S352L mutant relative to wild type enzyme.  
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Result of the crystal structure was supported by kinetics and ITC results. S352L 
mutant is inactive and ITC suggest that there is no detectable NAD+ binding to S352L 
mutant. Structural analysis revealed that Ser352 is in a polar environment and the 
hydroxyl group of Ser352 interacts with backbone carbonyl group of catalytic cysteine 
through a network of hydrogen bonding interaction (Fig. 4.12). There are two 
possibilities, why S352L mutant is inactive? Since mutation of serine to leucine do not 
have hydroxyl group, the hydrogen-bonding network connecting serine hydroxyl group to 
cysteine carbonyl group will be perturbed causing the conformational changes in catalytic 
cysteine and thus inactive protein. Secondly, Leucine is a non-polar residue and putting a 
non-polar group in a polar environment could break this hydrogen-bonding network. To 
investigate the two possibilities, S352A mutant was made and characterized kinetically 
and thermodynamically. Kinetic data suggest that S352A mutant has similar activity as 
wild type enzyme and its kinetic parameters are similar to wild type enzyme. ITC result 
also supports the kinetic data.  Wild type and S352A mutant has similar dissociation 
constant for NAD+ so NAD binding is not affected by S352A mutation. These results 
suggest that S352L mutant is inactive because the mutation puts a non-polar residue in to 
a polar environment. It is further corroborated by sequence alignment of aldehyde 
dehydrogenase, which shows that there is always a polar residue at Ser352.  
Due to the unavailability of 3-OH-P5C, oxidation of 3-OH-P5C by P5C 
dehydrogenase was studied in a coupled assay where 3-OH-P5C was generated in-situ by 
using PutA86-630 Y540S mutant. Since the efficiency of oxidation of proline and 
hydroxy-proline by PutA86-630 Y540S are different, different amount of enzyme was 
used for proline and hydroxy-proline. At 150 mM proline/hydroxy-proline, rate of 
production of P5C/3-OH-P5C was similar. However rate of NADH formation is 10 fold 
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higher when proline was used as substrate then when hydroxy-proline was used.  These 
results suggest that the oxidation of P5C by P5C dehydrogenase is more efficient than the 
oxidation of 3-OH-P5C. The result also shows that there is a decrease in the rate of 
NADH production with increasing concentration of proline. However, rate of production 
of P5C was similar at all the three concentration of proline. Although there is not a 
significant decrease in the rate of production of NADH with increasing concentration of 
hydroxy-proline, but rate of production of 3-OH-P5C was increased with increasing 
concentration of hydroxy-proline. This decrease in rate of oxidation of P5C/3-OH-P5C 
with increasing concentration of proline/hydroxy-proline may be due to the inhibition of 
P5C dehydrogenase by proline/hydroxy-proline.  
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Table 4.1: Human aldehyde dehydrogenase genes with their respective enzyme, substrate, 
oligomeric state, and PDB code (of homologue in case where structure of human enzyme 
is not known) 
Gene Enzyme Substrate Oligomeric 
state 
PDB ID 
ALDH1 ALDH1 Retinal Tetramer 1BXS, 1BI9 
ALDH2 ALDH2 Acetaldehyde Tetramer 1O05, 3INJ 
ALDH3 ALDH3 Fatty and aromatic aldehyde Dimer 1AD3 
ALDH4 ALDH4 Glutamate γ-semialdehyde Dimer or 
hexamer 
1UZB 
ALDH5 ALDH5 Propionaldehyde Tetramer 2W8N 
ALDH6 ALDH6 Aliphatic aldehyde, retinal  Not known  
ALDH7 ALDH7 Aliphatic and aromatic 
aldehyde 
 Not known  
ALDH8 ALDH8 unknown  Not known  
ALDH9 γABDH Amine aldehyde  Not known  
ALDH10 FALDH Aliphatic and aromatic 
aldehyde 
 Not known  
SSDH SSDH Succinic semialdehyde  Not known  
MMSDH MMSDH Methylmalonate semialdehyde   Not known  
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Table 2.2: Data collection and refinement statistics for HsP5CDH 
 Se-Met-1 Se-Met-2 native S352L 
space group P65 P65 P21 P1 
unit cell lengths (Å) a = 150.7,  
c = 191.6  
a = 150.7,  
c = 192.0 
a = 92.0  
b = 121.3  
c = 93.4  
β = 104.2  
a =66.2   
b =94.5  
c =182.4  
α = 76.9  
β = 87.4  
γ = 70.2 
wavelength 0.97918 0.97918 0.97949 0.97925 
resolution (Å) 50.0 – 2.85  
(2.95 – 2.85) 
50.0 – 2.50    
(2.59 – 2.50) 
50.0 – 1.95  
(2.02 – 1.95) 
62.3 – 2.55 
(2.69 – 2.55) 
no. of observations 661829 321938 489835 413388 
no. of unique reflections 113595 84960 139296 128074 
completeness (%) 100.0 (100.0) 99.7 (100.0) 96.5 (93.0) 97.1 (93.6) 
redundancy 5.8 (5.8) 3.8 (3.8) 3.5 (3.3) 3.2 (3.1) 
Rmerge(I) 0.100 (0.524) 0.075 (0.539) 0.049 (0.453) 0.102 (0.487) 
average I/σ 22.9 (4.4) 17.0 (2.5) 24.2 (2.2) 7.2 (2.1) 
Rcryst              0.2035 0.2001  
Rfreeb             0.2422 0.2461  
no. of protein residues     
no. of protein atoms      
no. of water molecules     
average B-factor (Å2)     
    protein     
    water     
    active site ligand     
rmsdc     
    bond lengths (Å)     
    bond angles (deg)     
Ramachandran plotd     
    favored (%)     
    allowed (%)     
    outliers (%)     
coordinate error (Å)e     
PDB accession code     
 
aValues for the outer resolution shell of data are given in parenthesis.  
b5% random test set.   
cCompared to the parameters of Engh and Huber.31  
dThe Ramachandran plot was generated with RAMPAGE.32 
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Table 4.3: Data collection and refinement statistics for MmP5CDHa  and Put2 
 
 Sulfate Glutamate 1-2 NAD+ 1-11 NADH 1-9 NADH/Glu  
1-3 
Put2 
space group P212121 P212121 P212121 P212121 P212121 P63 
unit cell lengths (Å) a = 85.2,  
b = 94.0,  
c =132.4  
  
a = 84.8,  
b = 93.9,  
c =132.2  
 
a = 84.9,  
b = 94.0,  
c =132.4  
 
a = 84.8,  
b = 94.2,  
c =132.2  
 
a = 84.9,  
b = 94.2,  
c =132.4  
 
             a=109 
b=181 
wavelength 0.97949 1.00000 1.00000 1.00000 1.00000                1.00 
resolution (Å) 50.0 – 1.30 
 (1.32 – 1.30) 
47.0 – 1.50  
(1.58 – 1.50) 
47.0 – 1.50  
(1.58 – 1.50) 
47.0 – 1.60  
(1.69- 1.60) 
47.0 – 1.50  
(1.58 – 1.50) 
           50-1.95                           
(2.02-1.95) 
no. of observations 914888 1222700 1221816 1013963 1231354           579452 
no. of unique 
reflections 
247337 168017 168338 137989 167674            88348 
completeness (%) 94.9 (86.0) 99.5 (96.5) 99.6 (97.6) 98.8 (97.7) 99.0 (96.1)        99.9(100) 
redundancy 3.7 (3.6) 7.3 (6.7) 7.3 (6.8) 7.3 (7.5) 7.3 (6.9)          6.6(6.5) 
Rmerge(I) 0.055 (0.502) 0.066 (0.418) 0.061 (0.399) 0.080 (0.521) 0.074 (0.480) 0.061(0.525) 
average I/σ 26.6 (2.4) 25.3 (4.8) 25.3 (4.9) 19.4 (3.6) 22.2 (4.3)       32.1(3.4) 
Rcryst  0.1316 0.1709 0.1767 0.1660 0.1665           0.1902 
Rfreeb 0.1601 0.1907 0.1961 0.1909 0.1860            0.2261 
no. of protein residues       
no. of protein atoms        
no. of water molecules       
average B-factor (Å2)       
    protein       
    water       
    active site ligand       
rmsdc       
    bond lengths (Å)       
    bond angles (deg)       
Ramachandran plotd       
    favored (%)       
    allowed (%)       
    outliers (%)       
coordinate error (Å)e       
PDB accession code       
  
aValues for the outer resolution shell of data are given in parenthesis.  
b5% random test set.   
cCompared to the parameters of Engh and Huber.31  
dThe Ramachandran plot was generated with RAMPAGE.32 
eMaximum likelihood-based coordinate error reported by PHENIX. 
 
 
 
 
 151 
Table 4.4: Kinetic parameters of wild type and mutant HsP5CDH 
 
Mutant/kinetic 
parameter 
Wild type S352A V470I 
Km(NAD+) 190±39 298±64 479±83 
Km(P5C) 174±44 145±43 278±67 
Vmax 251±24 159±16 272±30 
Ki(NAD+) 13±34 107±95 52±43 
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Figure Legend 
Figure 4.1 – Protomer structure of human P5C dehydrogenase. NAD+ binding   domain is 
shown in blue, catalytic domain in cyan and dimerization domain in magenta. 
Catalytic cysteine residue (Cys348) is drawn in sphere.  
Figure 4.2 – Structure of human P5C dehydrogenase dimer. Dimerization domain of one 
chain interacts with the catalytic domain of the other chain to make the 
dimer.  
Figure 4.3 – structural alignment of human and mouse P5C dehydrogenase. Human P5C 
dehydrogenase is shown in green and mouse P5C dehydrogenase is shown in 
magenta.  
Figure 4.4 – structural alignment of mouse and Thermus thermophilus P5C 
dehydrogenase. Mouse P5C dehydrogenase is shown in cyan and Thermus 
thermophilus P5C dehydrogenase is shown in magenta. 
Figure 4.5 – Protomer structure of human P5C dehydrogenase with dimer interface 
residues shown in red. 
Figure 4.6 – Structure of Mouse P5C dehydrogenase active site showing its direct 
interactions with sulphate ion. There are several water-mediated hydrogen 
bonding interactions between sulphate ion and protein not shown in figure. 
Fo - Fc map superimposed on sulphate ion and contoured at 3 σ.   
Figure 4.7 –  Structure of Mouse P5C dehydrogenase active site showing its interactions 
with bound product glutamate. Fo - Fc map superimposed on glutamate and 
contoured at 3 σ.   
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Figure 4.8 – Structural alignment of human P5C dehydrogenase in monoclinic and 
hexagonal crystal form. The loop from hexagonal crystal form is colored in 
blue and from monoclinic crystal form is colored in orange.  
Figure 4.9 – Structure of mouse P5C dehydrogenase complexed with NAD+. NAD+ is 
drawn in sticks and hydrogen bonding interactions between NAD+ and 
protein is shown with black dash.  
Figure 4.10 – Structure of mouse P5C dehydrogenase complexed with NADH. NADH is 
drawn in sticks and hydrogen bonding interactions between NADH and 
protein is shown with black dash. Overlapped is the structure of P5C 
dehydrogenase-NAD+ complex showing only NAD+. NAD+ is colored 
yellow. 
Figure 4.11 – Structure of human P5C dehydrogenase dimer showing single nucleotide 
polymorphism.  
Figure 4.12 - Structure of Mouse P5C dehydrogenase showing hydrogen-bonding 
network connecting Ser352 and Cys348. 
Figure 4.13 – Structural alignment of human P5C dehydrogenase (hexagonal form) with 
S352L mutant. Residues 348-352 of native enzyme is colored orange and 
S352L is shown in sticks with superimposed F0 map contoured at 1 σ. 
Residues 348-352 of S352L is moved towards the loop involved in NAD+ 
binding (colored wheat). 
Figure 4.14 – Stereo representation showing interaction of Glu447 with nicotinic ribose 
group and possible steric clash in S352L mutant. Mouse P5C dehydrogenase 
NAD+ complex (cyan) was superimposed on S352L mutant structure 
(green).  Residues 445-452 of mouse P5C dehydrogenase are shown in 
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sticks representation. F0 map, contoured at 1 σ, is superimposed on the 
residues 445-552 of S352L structure. Residues 348-352 of S352L mutant 
are shown in sticks and colored wheat. 
Figure 4.15 – Michaelis menten kinetics of native human P5CDH at different 
concentration of NAD+.  - 106.5 µM NAD+, - 177.5 µM NAD+,  - 
355 µM NAD+,   - 532.5 µM NAD+. Kinetic parameters were obtained 
from global fitting at all the four concentration of NAD+.  
Figure 4.16  – Michaelis menten kinetics of human P5CDH S352A mutant at different 
concentration of NAD+.  - 648 µM NAD+, - 324 µM NAD+,  - 135 
µM NAD+. Kinetic parameters were obtained from global fitting at all the 
three concentration of NAD+.  
Figure 4.17  – Michaelis menten kinetics of human P5CDH V470I mutant at different 
concentration of NAD+.  - 648 µM NAD+, - 324 µM NAD+,  - 135 
µM NAD+. Kinetic parameters were obtained from global fitting at all the 
three concentration of NAD+.  
Figure 4.18 – Raw ITC data of human P5C dehydrogenase S352L mutant. Each peak 
corresponds to the injection of 20 µl of 200 µM NAD+ in 50 mM Tris, 50 
mM NaCl, 0.5 mM EDTA, 1 mM THP, 10 % glycerol, pH 7.85 into 17.6 
µM of S352L in the same buffer.    
Figure 4.19 – Raw ITC data of human P5C dehydrogenase. Each peak corresponds to the 
injection of 20 µl of 200 mM NAD+ in 50 µM Tris, 50 mM NaCl, 0.5 mM 
EDTA, 1 mM THP, 5 % glycerol, pH 8.0 into 17.6 µM of native human 
P5C dehydrogenase in the same buffer. 
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Figure 4.20 – Binding isotherm generated by integrating each peak with respect to time 
after correcting for the dilution.  Cumulative heat () is plotted on y-axis 
with molar ratio on x-axis. Red line is the non-linear least square fitting of 
the data for single site binding.   
Figure 4.21 – Representative raw ITC data of human P5C dehydrogenase S352A mutant. 
Each peak corresponds to the injection of 20 µl of 200 µM NAD+ in 50 mM 
Tris, 50 mM NaCl, 0.5 mM EDTA, 1 mM THP, 5 % glycerol, pH 8.0 into 
17.6 µM of native human P5C dehydrogenase in the same buffer. 
Figure 4.22 – Binding isotherm generated by integrating each peak with respect to time 
after correcting for the dilution.  Cumulative heats of four different titration 
experiments are plotted on y-axis with concentration of NAD on x-axis. 
Global fitting of data was done by fitting four parameters simultaneously; 
association constant, enthalpy, stoichiometry, and baseline. 
Figure 4.23 – Schematics of coupled assay designed to study the oxidation of 3-OH-P5C 
by P5C dehydrogenase.  
Figure 4.24  – NADH formation by human P5C dehydrogenase at different concentration 
of proline and hydroxy-proline. - 150 mM Proline,  - 300 mM Proline, 
 - 450 mM Proline,  - 150 mM OH-Proline,  - 300 mM OH-proline, 
 - 450 mM OH-proline,  - 150 mM OH-Proline without human P5C 
dehydrogenase,  - 150 mM Proline without human P5C dehydrogenase. 
λex=340 nm, λem=460 nm, excitation and emission slit width was 10 nm.   
Figure 4.25  – NADH standard curve. NADH fluorescence was measured at different 
concentration of NADH using λex=340 nm, λem=460 nm, excitation and 
emission slit width= 10 nm. 
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Figure 4.26 – Equilibrium analytical ultracentrifugation data for human P5C 
dehydrogenase showing global fit to an ideal single fit model.  
Figure 4.27 – Equilibrium analytical ultracentrifugation data for mouse P5C 
dehydrogenase showing global fit to an ideal single fit model. 
Figure 4.28 – Equilibrium analytical ultracentrifugation data for Put2 showing global fit 
to an ideal single fit model. 
Figure 4.29 – Structural alignment of different aldehyde dehydrogenase showing 
conservation of Ser352 (a) and Glu447 (b). 
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Figure 5: Protomer structure of human P5C dehydrogenase 
 
 
 
Figure 4.2: Structure of human P5C dehydrogenase dimer. 
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Figure 4.3: structural alignment of human and mouse P5C dehydrogenase. 
 
 
 
Figure 4.4: structural alignment of mouse and Thermus thermophilus P5C dehydrogenase. 
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Figure 4.5: Protomer structure of human P5C dehydrogenase with dimer interface residues 
shown in red. 
 
 
Figure 4.6: Structure of Mouse P5C dehydrogenase active site showing its direct 
interactions with sulphate ion. 
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Figure 4.7: Structure of Mouse P5C dehydrogenase active site showing its interactions with 
bound product glutamate. 
 
 
 
Figure 4.8: Structural alignment of human P5C dehydrogenase in monoclinic and 
hexagonal crystal form. 
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Figure 4.9: Structure of mouse P5C dehydrogenase complexed with NAD+. 
 
 
 
Figure 4.10: Structure of mouse P5C dehydrogenase complexed with NADH. 
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Figure 4.11: Structure of human P5C dehydrogenase dimer showing single nucleotide 
polymorphism. 
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Figure 4.12: Structure of Mouse P5C dehydrogenase showing hydrogen-bonding network connecting 
Ser352 and Cys348. 
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Figure 4.13: Structural alignment of human P5C dehydrogenase (hexagonal form) with S352L 
mutant. 
 
 
 
Figure 4.14: Stereo representation showing interaction of Glu447 with nicotinic ribose group 
and possible steric clash in S352L mutant. 
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Figure 4.15: Michaelis menten kinetics of native human P5CDH at different concentration of NAD+. 
 
Figure 4.16: Michaelis menten kinetics of human P5CDH S352A mutant at different concentration of 
NAD+. 
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Figure 4.17: Michaelis menten kinetics of human P5CDH V470I mutant at different concentration of 
NAD+ 
 
 
 
Figure 4.18: Raw ITC data of human P5C dehydrogenase S352L mutant. 
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Figure 4.19: Raw ITC data of human P5C dehydrogenase.  
 
 
Figure 4.20: Binding isotherm for wild type human P5CDH generated by integrating each peak with 
respect to time after correcting for the dilution. 
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Figure 4.21: Representative raw ITC data of human P5C dehydrogenase S352A mutant. 
 
Figure 4.22: Binding isotherm for S352A mutant generated by integrating each peak with 
respect to time after correcting for the dilution. 
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Figure 4-23: Schematics of coupled assay designed to study the oxidation of 3-OH-P5C by 
P5C dehydrogenase. 
 
 
 
 
 
Figure 4-6: NADH formation by human P5C dehydrogenase at different concentration of proline and 
hydroxy-proline. 
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Figure 4-7: NADH standard curve. 
 
Figure 4-8: Equilibrium analytical ultracentrifugation data for human P5C dehydrogenase 
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Figure 4-9: Equilibrium analytical ultracentrifugation data for mouse P5C dehydrogenase 
 
 
 
Figure 4-10: Equilibrium analytical ultracentrifugation data for Put2. 
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Figure 4-11: Structural alignment of different aldehyde dehydrogenase 
      (a) -  
 
(b) 
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